University of Tennessee, Knoxville

TRACE: Tennessee Research and Creative
Exchange
Doctoral Dissertations

Graduate School

8-2015

Blueberry polyphenols as natural antimicrobial agents against
foodborne viruses: Towards understanding their mechanism and
applications in food systems
Snehal Shrikant Joshi
University of Tennessee - Knoxville, sjoshi5@vols.utk.edu

Follow this and additional works at: https://trace.tennessee.edu/utk_graddiss
Part of the Food Microbiology Commons

Recommended Citation
Joshi, Snehal Shrikant, "Blueberry polyphenols as natural antimicrobial agents against foodborne viruses:
Towards understanding their mechanism and applications in food systems. " PhD diss., University of
Tennessee, 2015.
https://trace.tennessee.edu/utk_graddiss/3503

This Dissertation is brought to you for free and open access by the Graduate School at TRACE: Tennessee
Research and Creative Exchange. It has been accepted for inclusion in Doctoral Dissertations by an authorized
administrator of TRACE: Tennessee Research and Creative Exchange. For more information, please contact
trace@utk.edu.

To the Graduate Council:
I am submitting herewith a dissertation written by Snehal Shrikant Joshi entitled "Blueberry
polyphenols as natural antimicrobial agents against foodborne viruses: Towards understanding
their mechanism and applications in food systems." I have examined the final electronic copy of
this dissertation for form and content and recommend that it be accepted in partial fulfillment
of the requirements for the degree of Doctor of Philosophy, with a major in Food Science and
Technology.
Doris D'Souza, Major Professor
We have read this dissertation and recommend its acceptance:
Irene Hanning, Gina Pighetti, Melissa Kennedy
Accepted for the Council:
Carolyn R. Hodges
Vice Provost and Dean of the Graduate School
(Original signatures are on file with official student records.)

Blueberry polyphenols as natural antimicrobial
agents against foodborne viruses: Towards understanding
their mechanism and applications in food systems

A Dissertation Presented for the
Doctor of Philosophy
Degree
The University of Tennessee, Knoxville

Snehal Shrikant Joshi
August 2015

DEDICATION

To Aai and Baba (Jyotsna and Shrikant Joshi) for their immense love and support

ii

ACKNOWLEDGEMENTS

I am grateful to several people who helped throughout my graduate school journey.
Firstly, I would like to thank my parents Shrikant and Jyotnsa Joshi and my entire family. Their
love, support and encouragement have helped me achieve my goals. They all are a source of
strength and inspiration to me.
I would like to express my deep gratitude to Dr. Doris D’Souza for her guidance and
encouragement during these years. I would also grateful to all my committee members, Dr. Gina
Pighetti, Dr. Irene Hanning and Dr. Melissa Kennedy for their input and guidance throughout my
graduate program.
I have had the pleasure of working with many people during these years, and I am very
thankful for the great times we have shared and for their help. A very special thanks to all of my
friends, lab mates, classmates and staff in the Department of Food Science and Technology for
creating a friendly learning and working environment. Snigdha Sewlikar, Dr. Valladares and Dr.
Chen you made all the difficult days seem so easy.
I also want to thank all my friends from Mumbai for always being there for me whenever
I needed them. Shobs, you being in the US always made me feel close to home. My heartfelt
thanks to Sagar and Sarvesh, you both have been my pillars of support through out these years
and made Knoxville home to me. A very mention to all my friends in Knoxville without whom
this journey would have been incomplete. Thank you for all the wonderful experiences we have
all shared.

iii

ABSTRACT
Foodborne viruses are recognized as public health concerns worldwide and therefore
effective strategies to control their spread are being researched. Blueberries are known for their
health benefits and antimicrobial properties. This study aimed to (1) determine the antiviral
effects of blueberry juice (BJ) and blueberry proanthocyanidins (B-PAC) against the infectivity
of hepatitis A virus (HAV), Aichi virus (AiV) and human norovirus surrogates (feline calicivirus
(FCV-F9) and murine norovirus (MNV-1)) at 37ºC over 24-h using standard plaque assays; (2)
evaluate antiviral effects in model foods (apple juice (AJ) and 2% milk) and simulated gastric
conditions at 37oC; and (3) determine the mechanism of action of B-PAC by comparing activity
of monomeric catechins, procyanidin B2, B-type PAC from blueberries (B-PAC) and A-type
PAC from cranberries (C-PAC), effects on viral structure using transmission electron
microscopy, and on adsorption and replication. FCV-F9, MNV-1, HAV and AiV titers were
reduced to undetectable levels after 5 min, 3-h, 30 min and 3-h with 1, 1, 2, and 5 mg/ml B-PAC,
respectively. BJ reduced FCV-F9, MNV-1, AiV to undetectable levels and HAV by ~2 log
PFU/ml after 3, 6, 24 and 24-h, respectively. All tested viruses were reduced to undetectable
levels within 15 min with B-PAC (1, 2 and 5 mg/ml) in AJ (pH 3.6). B-PAC effects decreased in
milk, where FCV-F9, MNV-1, HAV and AiV were reduced by ~ 1 log PFU/ml with 5 mg/ml
after 24-h. B-PAC at 5 mg/ml in simulated intestinal fluid reduced all tested viruses to
undetectable levels within 30 min. Monomeric catechins and procyanidin B2 were less effective
than the polymeric B-PAC. Time of addition assays indicated that B-PAC had modest effects in
preventing viral adsorption, with no significant effect on viral replication. TEM observations
revealed moderate effects on virus structure with either damaged viral capsid or virus binding to
iv

B-PAC, possibly preventing virus attachment to host cells. Overall, this study demonstrated the
ability of BJ and B-PAC to reduce viral titers in model food systems and under simulated gastric
conditions, suggesting their potential as preventive and therapeutic options against foodborne
viral illnesses.

Keywords: blueberry polyphenols, human norovirus surrogates, hepatitis A virus, Aichi virus
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Introduction

Foodborne enteric viruses are commonly associated with non-bacterial acute gastroenteritis in
humans and animals. The epidemiologically significant foodborne viruses include human
noroviruses, hepatitis A virus, rotaviruses, Aichi virus, hepatitis E virus, adenoviruses, sapovirus,
astrovirus, parvoviruses and other enteroviruses. These viruses are a growing cause of public
health concern in the United States as well as worldwide with an increasing number of outbreaks
reported every year. For instance, in the US among the 31 pathogens that are responsible 9.4million foodborne illnesses, human noroviruses alone are reported to be responsible for an
estimated 5.5 million foodborne illnesses. Foodborne viruses can be transmitted through the
fecal-oral route by contaminated food and water, via person-to-person, contact with
contaminated surfaces, and aerosolization. At-risk foods associated with viral outbreaks, include
filter-feeding shellfish, fresh produce, juices, bakery items, deli meats, and other ready-to-eat
(RTE) foods or undercooked foods. However, some of these viruses including human
noroviruses and Aichi virus currently do not have vaccines available for their control. Give their
widespread prevalence in the food chain, effective natural alternatives to control their spread are
being researched. Natural plant extracts have been used for their valuable medicinal properties
since centuries. Extracts from plant and fruit sources are known to contain abundant secondary
metabolites mainly phenolic compounds including but not limited to anthocyanidins,
proanthocyanidins, catechins, epicatechin gallate and tannins. Plant extracts are being studied
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extensively as sustainable sources of potential therapeutic options and also being screened for
their antiviral potential.
Blueberries and its polyphenols are known for their potential health benefits including
anticarcinogenic, neuroprotective, cardioprotective, antibacterial, and antiviral properties.
Blueberries contain structurally related polyphenols, including anthocyanins, flavonoids, and
proanthocyanidins (PAC), sometimes referred to as condensed tannins (1). Human norovirus
surrogates such as feline calicivirus (FCV-F9) and murine norovirus (MNV-1) have been studied
for survival in commercial blueberry juice (BJ) at 4ºC, where FCV-F9 was undetectable after 24
h from initial 5 log PFU/ml, whereas MNV-1 showed minimal reduction after 21 days at 4ºC (2).
Therefore, blueberries and blueberry phenols could potentially be used as part of a diet to prevent
or treat human norovirus related gastroenteritis. This study aimed to explore the antiviral effects
of blueberry polyphenols and blueberry juice against foodborne viruses (cultivable human
norovirus surrogates and hepatitis A virus) in vitro at 37oC, in model food systems, and under
conditions mimicking digestion (simulated gastric conditions). In addition, this study also
attempted to understand the mode of action of monomeric, dimeric and polymeric units of
blueberry polyphenols against the tested viruses. Thus, insights on the benefits of blueberry
polyphenols in improving gastrointestinal health by preventing or alleviating human norovirus
and hepatitis A virus disease symptoms were obtained.

2

Chapter 1 Review of literature
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Parts of this chapter have been submitted as chapters that have been accepted for
publication.
1. Joshi, S.S. and D’Souza D.H. (2014). Health Benefits of Grape Seed Extract, “GRAPES”: Production,
Phenolic Composition, and Potential Biomedical Effects, Nova Science publishers Inc., New York.
2. D’Souza D.H. & Joshi S.S. (2015). Foodborne viruses of human health concern. Encyclopedia of Food
and Health. Elsevier Publications.

Introduction to Foodborne Viruses
Annually, in the United States, among the 31 pathogens that cause an estimated 9.4million foodborne illnesses, human noroviruses alone are reported to be responsible for an
estimated 5.5 million foodborne illnesses (58%), 26% hospitalizations, and 11% deaths (3). As
an overview about viruses, they are smaller in size (nM) and unique properties than bacterial
pathogens, with lesser complexity. Viruses are obligate intracellular parasites that are dependent
on a host cell to replicate and unlike bacteria cannot multiply in foods or the environment (4, 5).
Foodborne viruses are generally environmentally stable, survive adverse conditions and are
resistant to extreme pH conditions and enzymes of the gastrointestinal tract (4). They have low
infectious doses, as few as 10-18 human noroviral particles can cause gastrointestinal illness (6).
Foodborne viruses can be transmitted through the fecal-oral route by contaminated food
and water, via person-to-person, contact with contaminated surfaces, and aerosolization (7).
Viral contamination of foods often occurs due to poor hygiene practices of infected
foodhandlers, where public education and enforcement of hygienic practices can help reduce
outbreak incidence. Fecally polluted waters that flow into farmlands, can contaminate crops and
also shellfish can accumulate viruses in their gastrointestinal tract. Contaminated fresh produce
and shellfish when eaten raw or undercooked can cause illness. At-risk foods associated with
viral outbreaks, include filter-feeding shellfish, fresh produce, juices, bakery items, deli meats,
and other ready-to-eat (RTE) foods or undercooked foods. Viruses that are associated with
4

foodborne and waterborne diseases include human noroviruses (HNoV), hepatitis A virus,
rotaviruses, hepatitis E virus, adenoviruses, sapoviruses, astroviruses, aichi virus, parvoviruses,
and other enteroviruses (8).
Human Noroviruses
Human noroviruses are considered as major causes of non-bacterial gastrointestinal outbreaks
worldwide. Human noroviruses (HNoVs) belong to Caliciviridae family that consists of five
major genera, Norovirus, Sapovirus, Vesivirus, Lagovirus, and the recent addition of Becovirus
or Nebovirus (9). HNoVs were first reported to be discovered in an elementary school outbreak
in 1968 in Norwalk, Ohio, where 50% of students and teachers developed gastrointestinal illness,
from which the name “Norwalk-like” virus was derived by Albert Kapikian in 2000. HNoV
transmission occurs all year round, however, outbreaks peak in winter (10). ‘Winter vomiting
disease’ is the common seasonal syndrome caused by HNoV infection, characterized by mild
gastroenteritis and symptoms like nausea, vomiting, abdominal cramps, fever and malaise,
though emerging virulent strains are capable are causing death in the elderly and
immunocompromised (11). The average incubation time of HNoV is 24-48 h and the selflimiting symptoms last from 18 to 48 h. Infected individuals can shed viruses for 72 h (and even
longer, >week) after the first symptoms appear (12). This is an important consideration for food
handlers/workers, who need to maintain good hygienic practices to prevent transmission upon
return to work. In addition to outbreaks associated in food settings, HNoV outbreaks are reported
to recur yearly on cruise-ships, in elderly care facilities, and in closed environments.
Noroviruses are non-enveloped, small about 27 to 32 nm in size, and possess a singlestranded positive-sense RNA enclosed in a capsid (outer shell protein), with a buoyant density of
5

1.33 to 1.41g/ml (13). HNoVs have icosahedral symmetry, with a capsid that comprises of 90
capsomeres protruding from the shell made of 90 dimers of capsid protein. The genome is about
7.3-7.7 kb long with three open reading frames (ORF’s) (14). ORF1 encodes for a polyprotein
that is cleaved to produce the N-terminal protein, the enzyme nucleoside triphosphatase, a 3Alike protein, the genome-linked viral protein (VpG), a 3C-like protease, and RNA-dependent
RNA-polymerase (15). ORF2 encodes for the major capsid protein, viral protein, VP1; and ORF
3 encodes for a minor viral structural protein, VP2. Based on sequence analysis, the genus
Norovirus is further divided into five genogroups, GI, GII, GIII, GIV and GV, and genogroups
GI, GII and GIV, specifically infect humans (16, 17). Genogroup III includes bovine enteric
calicivirus that infects cattle, and genogroup V infects mice. These genogroups are further
subdivided into at least 32 genetic clusters (9, 18). Among the genogroups I and II, 8 genotypes
are currently recognized in genogroup I and 19 genotypes are recognized in genogroup II.
HNoV GII.4 genotype during the past decades has been the predominant cause of outbreaks in
the United States, Europe, and Oceania that were responsible for 70%–80% of all HNoV
outbreaks (particularly in health care settings) (19). More recently, canine norovirus infecting
dogs was discovered with strains classified into genogroups IV and VI (20).
HNoV binds to the histoblood group antigens in human intestinal epithelial cells, where
the site of replication is considered as the upper intestinal tract (21). Genetic determinants for
these blood group antigens play a role in susceptibility of an individual to HNoV infection.
Human volunteer studies have shown that H type I antigen likely serves as the receptor for
HNoV, encoded by the fucosyltransferase (fut2) gene (22). Individuals that are recessive for this
gene, lack the Type I antigen, and are inherently resistant to HNoV infections (22).
6

HNoV GI and HNoV GII can survive in the environment and were detected after 1-week
storage on inoculated coupons at ambient temperature using RT-PCR (23). HNoVs are known to
survive low pH of 2.7, can retain infectivity after 60°C for 30 min and also after exposure to 20%
ether at 4°C for 18 h (13). Their resistance to inactivation is found to be higher in foods where
steaming of mussels did not cause any significant reduction in HNoV titers (24). HNoVs were
also found to be resistant to chlorine inactivation with a free residual chlorine of 0.5 to 1.0
mg/mL (25).
The inability to cultivate HNoVs in the laboratory has hindered the development of
vaccines and effective control measures. There is no vaccine available to date for HNoV
prevention. Cultivable surrogates such as feline calicivirus (FCV-F9) and murine norovirus
(MNV-1) have been extensively used to understand antigenicity of HNoVs and evaluate methods
of inactivation. Recently, Tulane Virus and porcine enteric Sapovirus have also been considered
as alternate surrogates. FCV-F9 of the Caliciviridae family, is a small rounded, non-enveloped,
single-stranded RNA virus with a 7.7 kb genome, has 3 ORFs, and is transmitted through air via
fomites (26). However, since it is transmitted via a respiratory route, it may not completely
mimic the survival of HNoV in the environment. In addition, unlike HNoVs, FCV-F9 is sensitive
to low pH of 2.0 to 4.0 and pH 10.0 (27).
MNV-1 is currently the only known norovirus that replicates in the laboratory in murine
macrophage RAW 264.7 cells (28). MNV-1 belongs to genogroup V norovirus, sharing sequence
similarity to genogroup II that mainly infect humans (29, 30). MNV-1 is similar to HNoVs in
immunological, biochemical, genetic and molecular properties, as MNV-1 is an icosahedral,
non-enveloped, single-stranded RNA virus with 3 ORFs, 28-35 nm in diameter (28). Although it
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causes a different disease in mice, it is transmitted via the fecal oral route similar to HNoVs (27).
Unlike FCV-F9, it is less sensitive to pH within ranges of 2.0 to 10.0, however the thermal
inactivation parameters processes like pasteurization at 63oC were reported to be similar for both
FCV-F9 and MNV-1 (27). D-values required for heat inactivation of FCV-F9at temperatures of
50, 65 and 72oC were reported to be 19.95 ± 0.70, 0.72 ± 0.01 and 0.21 ± 0.01 min respectively.
For MNV-1 the reported D-values at 50, 65 and 72oC at were 36.28±3.21, 0.77±0.03 and
0.25±0.01 min, respectively (31).
Regarding application of surrogates for inactivation studies, both 200mg/ml sodium hypochlorite
and 2% trisodium phosphate could reduce MNV-1 by 2-3 log PFU/ml and FCV-F9 to
undetectable levels, respectively after 30 s at room temperature(32). Ozone at 6.25 ppm caused
a~2-log Tissue culture infectious dose (TCID50/ml) reduction of FCV after 5 min and 2 log
TCID50ml-1 reduction of MNV-1 after 3 min on lettuce and green onions (33). Hydrogen
peroxide vapors (30% w/w) were found to cause 4 log reduction of FCV-F9 after 20 min on
stainless steel, ceramic tiles, and PVC surfaces (34). MNV-1 at 7 log PFU was completely
inactivated at a pressure of 450MPa after 5 min at 20oC, while 250 MPa at 20oC for 5 min
reduced FCV titers by 5.1 log PFU/ml(35, 36).
Recently, Tulane virus (TV) representing a new genus Recovirus of the Caliciviridae
family was isolated from the stool samples of a captive juvenile rhesus macaques
(Macacamulatta) at the Tulane National Primate Research Center. TV is 36 nm in diameter,
icosahedral in symmetry (37). TV has the shortest known genome of around 6.7 kb among the
known caliciviruses, contains 3 ORFS and lacks the poly (A) tail. Pairwise homology and
phylogenetic analysis of non-structural proteins of TV revealed highest identity with HNoVs.
8

TV can be readily grown in vitro in LLC MK2 (rhesus macaque kidney) cells. TV can
bind to histoblood group antigens like HNoVs, suggesting that the antigenic determinants and
structural properties might be comparable to HNoVs (30). Studies have shown no significant
differences in heat inactivation parameters between MNV-1 and TV, though MNV-1 was found
to be more pH stable and tolerant to chlorine, while significant reduction in TV titers were
obtained at pH 2.0 and 9.0 and after 2 ppm chlorine treatments (30, 38). Therefore, the choice of
appropriate cultivable surrogates for HNoVs is still debatable.
Porcine sapovirus (Cowden strain), an enteropathogen that causes gastroenteritis in
gnotobiotic pigs is as another HNoV surrogate that can be cultivated in the swine kidney cell
line, LLC-PK (39). Both porcine SaV and HNoV showed similar resistance to treatments at
56oC for 30 min and 2 h and with 2.5mg/Lor 10mg/L sodium hypochlorite for 1 min; similar to
HNoV’s, porcine SaV is stable at pH 3.0 to 8.0 (39). All these findings strongly support the use
of porcine SaV as a surrogate to study HNoV.
Virus like particles (VLPs): Along with the use of above viruses as HNoV surrogates,
virus like particles (VLPs) have also been used to understand and study HNoV replication in
vivo or to develop vaccines (40). These virus-like particles (VLPs) are non-infectious (they lack
the genome) of HNoVs and were first expressed in baculovirus-infected insect cells (41). The
VLP’s produced mimic the antigenic structure of the virus and also are acid and heat stable.
These VLP’s are also highly immunogenic and produce an immune response when delivered
intranasal, making them an ideal candidate for use in developing vaccines (42). VLPs were also
shown to bind to carbohydrate histo-blood group antigen (HBGA) displayed on mucosal cell
surfaces similar to human norovirus (43).
9

Currently, there is no specific anti-viral treatment against HNoVs. Gastroenteritis and
dehydration can be treated by oral or intravenous fluid therapy. To date, there is no vaccine
available against HNoVs, the major barrier being the inability to culture them in vitro. Human
volunteers re-infected with HNoV after exposure were found to be susceptible to the same strain
as well as heterologous strains (44, 45). The spread and contamination can be prevented by
proper sanitation and hygienic food handling practices or by heat, chemicals, or processing
conditions described above (CDC, 2013).

Hepatitis A virus
Hepatitis A virus (HAV) belongs to the Picornaviridae family and is a positive-sense singlestranded non-enveloped RNA virus ranging in size from 27-32 nm, similar to HNoVs. The
genome is 7.5 kb in length and unlike HNoVs consists of a single open reading frame. The P1
region of the genome encodes for three major viral capsid proteins VP1, VP2, and VP3. P2 and
P3 regions encode for nonstructural proteins required for RNA replication and virion formation
(46, 47). Only one serotype of HAV has been identified to date and a single exposure can render
life-long immunity in an individual (48). However, genetic diversity in the strains worldwide led
to their classification into seven genotypes designated I to VI. Genotypes I to IV are associated
with human illnesses and genotypes V to VI include strains are obtained from affected simians
(49).
The largest foodborne viral outbreak associated with 292,301 cases of HAV was attributed to
eating raw clams in Shanghai, China in 1988 (50). The most recent HAV outbreak was linked to
the frozen antioxidant mix that contained pomegranate seeds imported from Turkey (51). About
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165 people were confirmed to be ill following the consumption of this mix and the genotype 1B
was implicated where it was reportedly detected in 117 stool samples of the infected persons
(51). Several other outbreaks have been linked to sundried tomatoes and green onions (52-54).
Given the amount of imports from different regions of the world and increasing international
travel there has been a rise in the number of HAV cases seen every year (55).
The average incubation period is long (unlike the short incubation period of HNoVs),
approximately 28 days with severe symptoms that include jaundice, dark urine, vomiting, fever
and weight loss that can last for 4 to 6 weeks. Among older children and adults, infection is
usually symptomatic for 2 months, with jaundice occurring in 70% of patients. There are 4
phases of HAV infection: the asymptomatic incubation phase lasts for 10 to 50 days; prodromal
or preicteric (56, 57) phase lasts for several days to week, characterized by fatigue, nausea, and
loss of appetite, fever, dark urine, diarrhea and pale stools; the icteric phase where jaundice
develops along with increase in liver enzymes (namely serum transaminase and alkaline
phosphatase) and rise bilirubin levels in blood resulting in yellowing of urine and leading to
jaundice, and in the 4th phase (convalescent) symptoms start resolving with relapse that can occur
in 3-20% of the cases (58).
There are few strains of HAV (HM-175, HAS-15, MBB 11/5) that are cell-culture
adaptable and maintained using fetal rhesus monkey kidney (FRhK-4) and/or human fetal lung
fibroblast (MRC-5) cells. These strains produce cytopathic effects causing cell death by inducing
apoptosis (59, 60), and used in research for inactivation studies.
HAV is highly stable in the environment and retains infectivity in mineral water stored at
room temperature even after 300 days (61). HAV remains infectious after a month at ambient
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temperatures on environmental surfaces like stainless steel (62). HAV survives for >4 h on hands
after experimental exposure (63) and during prolonged storage of spinach leaves at 5.4°C, with a
D-value of 28.6 days (64). Sixty-two percent of inoculated HAV survived on romaine lettuce
leaves that were stored for 12 days in a sealed-atmosphere plastic package at 4°C (65).
HAV survives in acid marinade at pH 3.75 over 4 weeks (66), and can retain its infectivity
at pH 1.0 even after 5 h (67). HAV infectivity can be retained after 60 min at 60°C, being
partially inactivated after 10-12 h at 56°C and can be inactivated in shellfish after heating at
85°C to 90°C for 1.5 min (67, 68), and reduced to undetectable levels from 7 log PFU/ml at
450MPa hydrostatic pressure for 5 min (69). These survival features play a signiﬁcant role in the
transmission of HAV. Once a person is infected with HAV, there are no specific treatment
options available. However, symptoms of HAV infection may be alleviated by appropriate
patient care that includes adequate hydration, nutrition, rest, and anti-emetics (70). For
prevention, immunoglobulin (Ig) therapy is effective when administered within two weeks of
viral exposure (through passive immunity). As preventive measures, inactivated and heat-killed
vaccines against HAV are commercially available, that provide immunity against HAV for >20
years or lifetime (71). The U.S. Centers for Disease Control and Prevention (CDC) recommend
routine vaccination against HAV for children aged between 12 to 23 months (55). When
economically feasible, vaccination of food-handlers is recommended to prevent HAV
transmission and to prevent outbreaks.
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Aichi virus
Aichi virus (AiV) of the genus Kobuvirus in the Picornaviridae family was first isolated in 1989
from patient stool samples in a gastrointestinal outbreak involving oysters in Aichi, Japan (72). It
has a positive-sense single-stranded RNA and a poly (A) tail, with a single ORF encoding for
structural proteins VP0, VP1 and VP3, and non-structural proteins 2A, 2B, 2C, 3A, 3B, 3C, 3D
(73). AiV’s are classified into three distinct genotypes A to C (74). AiV virions are icosahedral,
30 nm in diameter with three capsid proteins (73). AiV-related gastrointestinal cases have been
reported from Asian, African, European and South American countries indicating its
geographical spread and prevalence (75-80). AiV has been known to survive (without reduction)
high pressure processing (HPP) treatment of 600 MPa for 5 min in minimum essential growth
medium (MEM) with 10% fetal bovine serum (81). However, AiV was reduced by 1.87, 2.49
and 4.59 log TCID50mlrespectively when treated by 240 mW s-2 of ultraviolet light treatment,
that can be used to reduce AiV on fresh produce like strawberries, green onions and lettuce (82).
AiV isolates were stable in 10% chloroform and MEM (pH 3.5) for 3h and survives heating at
50oC and 60oC for 30 min (72).
Hepatitis E virus
Hepatitis E virus (HEV) is a small non-enveloped RNA virus, 32-34 nm, primarily transmitted
through the fecal-oral route usually through contaminated water (83, 84). This virus is mainly
predominant in developing countries in Asia and Africa (85). HEV of the genus Hepevirus in the
Herpeviridae family, comprises of a 7.2 kb single-stranded positive-sense RNA with three open
reading frames (ORFs) (86). The average incubation period for HEV infection is between 2 to 10
weeks, with two distinct phases of illness. The pre-icteric phase is characterized by fever,
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anorexia, vomiting and abdominal pain, while the icteric phase is characterized by jaundice and
is self-limiting. Viral shedding begins 1-2 weeks before and 2-4 after onset of symptoms. A
significant rise in serum alanine aminotransferase and aspartate aminotransferase occur, that is
used as detection methods of liver injury (87). Due to its long incubation period, association of
HEV with particular foods has not been established, however recent studies suggest HEV
transmission is linked to consumption of uncooked pork meat (88). There is no specific treatment
except patient care as described above for HAV symptom alleviation. Pegylated interferon
administration has been tried in chronic infections with moderate success (89). Vaccine trials
have been under study to determine preventive measures.

Rotavirus
Rotavirus (RV) of the Reoviridae family has a multilayered non-enveloped icosahedral capsid,
ranging from 60-100 nm in size and is easily distinguishable from HNoVs or HAV by electron
microscopy. RV has 11 segments of double-stranded RNA that code for structural proteins (VP1
to VP8) and non-structural proteins. Rotavirus (RV) is a common cause of acute gastroenteritis
in children younger than 5 years (90). RV was first discovered in 1973 with electron micrographs
of intestinal and stool biopsies of children suffering from gastroenteritis, with a typical wheel
shape and hence the Latin name “Rota” meaning wheel (91). The incubation period for human
RV is around 1 to 3 days. Symptoms occur 48 h after RV infection that include watery diarrhea,
abdominal pain, vomiting, and dehydration, with severe diarrhea resulting in high mortality rates
around the world (92). In 1980’s, there were 870,000 deaths linked to RV infection globally,
with current numbers around 450,000/year, and developing countries like the Democratic
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Republic of the Congo, Ethiopia, India, Nigeria, and Pakistan accounted for > half of total
rotavirus related deaths, with India accounting for 22% (98,621) of deaths (93, 94). Many RV
outbreaks are known to occur due to contaminated water and unhygienic and unsanitary
conditions (95, 96).
Human RV can survive and retain antigenicity after 5 mgml-1 chlorine treatment for 60
min (97), and is resistant to wipes containing 1000 ppm chlorine on stainless steel surfaces (98).
High pressure processing at 350 MPa at 4oC caused a 1.1 log PFU reduction in RV titers (99).
RV subjected to wet (100oC) and dry (60oC) heat for varying periods of 1-20 min led to changes
in virion morphology and loss of smooth capsid layer (100). Commercial cranberry and grape
juices at native pH could reduce RV infectivity after 5 min at 23 oC (101). Other natural
substances such as persimmon extract and wattle extract (0.5% solution) reduced human RV
strain Wa titers by 5.3 log PFUml-1 after 3 min at room temperature (102).
Animal model-systems have been developed to study and improve strategies for
protection against infection from various RV serotypes/isolates. Two Simian RV strains SA11
and Rhesus Rotavirus (RRV) are being used as reference strains worldwide and some of the
currently available reassortment vaccines are based on the RRV strain(103, 104). As a preventive
measure against human RV infection, the World Health Organization (WHO) recommends
vaccination that has significantly reduced rotavirus-related gastroenteritis and mortality (105).
Sapovirus
Sapovirus of the Caliciviridiae family is a positive-sense single-stranded 7.5 kb RNA virus, 4146 nM in diameter, that infects humans and pigs (106). Sapporo virus (SaV), the human
prototype was first identified in an infant home outbreak in Sapporo, Japan in 1977. It has 10
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spikes on the outer surface. SaV is divided into five genogroups, GI to GV; Genogroups GI, GII,
GIV and GV infect humans and GIII infects pigs. Genomes of GI, GIV, and GV contain three
open reading frames (ORF’s) and GII genomes contain two ORFs (107, 108). RNA-dependent
RNA polymerase and a major capsid protein (VP1) are encoded by ORF1, ORF2 encodes a
small protein similar to VP2 of NoVs and ORF3 encodes for a protein with unknown function
(39). Outbreaks of SaV are less frequent than HNoV, however significant increase in SaV
outbreaks has occurred in various settings such as elementary schools, high schools, hospitals
and hotels (109). SaV is associated with treated and untreated sewage, and river water (110). The
average incubation time is ~24-48h with symptoms like diarrhea, abdominal pain, nausea,
vomiting, chills, malaise and fever (111). Human SaVs like HNoVs are uncultivable (112, 113).
As mentioned above, porcine sapovirus that is cultivable in the lab is also studied as a surrogate
for HNoVs (39).
Adenovirus
Adenoviruses (AdV) were first isolated from civilians and Army recruits who had respiratory
disease (114, 115). AdVs of the genus Mastadenovirus, are 90-100 nm, non-enveloped, contain
26-45 kb double-stranded DNA enclosed in an icosahedral shell. Clinical manifestations of
HAdVs range from upper and lower respiratory tract infections, pneumonia, to gastroenteritis
and urinary tract infections (116, 117). HAdVs cause mild and self-limiting disease, and severe
clinical presentations if any include cystits, enteritis, encephalitis and pneumonia (118). HAdV
serotypes 40 and 41 are the second leading cause of viral gastroenteritis in children after
rotavirus (119). Symptoms like diarrhea, dehydration, vomiting, and fever develop after an
incubation period of 8-10 days and last for 7-8 day, with shedding for 7-14 days after infection
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(120).
Other enteric viruses
Astroviruses are small, ~30 nm in size, star-shaped, non-enveloped RNA viruses, that
were first identified in 1975 in children suffering from diarrhea in a maternity ward in England
(121). Their name originates from the Greek word ‘astron’ meaning star, which represents the
five star-like projections on the virus (122). Astroviruses belong to the family Astroviridae that is
divided into two genera; Mamastroviridae (that infect mammals) and Avastroviridae (that infect
avians) (123). Their genome is about 6.8 to 7.9 kb with a 5’ untranslated region and 3 ORFs,
ORF1a, ORF1b and ORF2. ORF1 encodes a RNA dependent RNA polymerase and a protease
while ORF2 encodes for the viral capsid (124). Astroviruses are not easily cultivable in vitro,
hence the serological classification is mostly established on nucleotide and amino acid variability
of ORF2 (124). Till date, there are eight known serotypes of human astroviruses (HAstV), with
type 1 being the most prevalent (125-127). Along with the genetic diversity of ORF2, HAstV are
further classified into genogroups A and B; genogroup A includes serotypes 1 to 5 and 8,
genogroup B includes serotypes 6 and 7 (128). When culturable, the virus is grown using the
human colon carcinoma (Caco-2) cell line (129).
HAstVs are reported to be a common cause of gastroenteritis in children (130).
Symptoms related to HAstV develop 2-3 days after infection and include diarrhea, vomiting,
abdominal pain, headache and dehydration. However, affected persons may not require
hospitalization since the symptoms are self-resolving (120, 131). HAstV is known to infect the
immunocompromised, elderly, and healthy adults, though children under the age of two are most
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prone to infection (124, 132). Astrovirus is known to survive in water and surfaces for 60 days at
4oC and in water at 20oC and after 2 h in 1mg/L free chlorine (133).
Parvovirus of the Parvoviridae family is a small, 18-26 nM, non-enveloped singlestranded 5kb DNA virus, discovered in 1974 while testing for hepatitis B surface antigen (134,
135). It is icosahedral with a buoyant density of 1.39 to 1.42 g/ml. Parvovirinae are divided into
three genera based on transcription maps, their terminal repeats and replication; Parvovirus,
(autonomous), replication with helper virus Dependovirus and in erythrocytes Erythrovirus, and
only Dependovirus and Erythrovirus are known to infect humans(136, 137). Parvovirus genome
has 2 ORFs, transcribing viral proteins VP1 and VP2 and non-structural proteins, with VP2 the
major structural protein comprising of 96% of total capsid protein (138).
Parvoviruses are resistant to pH between 3 and 9 and at 56oC for 60 min, but can be
inactivated by formalin and gamma-radiation (139). Parvoviruses have been linked to shellfish
and the “cockle agent” parvovirus was associated with a large outbreak related with
contaminated cockles in the UK involving around 800 people (137, 140).
With this information on the foodborne viruses and their transmission along with the lack
of available vaccines in most cases, novel methods to control their spread are being researched.
Ideally, methods should be cost-effective, easy-to-use, sustainable and natural with consumer
appeal. Natural plant extracts and in particular plant polyphenols can serve as attractive alternate
therapeutic or preventive options in the absence of vaccines and effective control measures.
Natural plant extracts
As indicated above, in the current absence of vaccines or effective treatment options for HNoV
infections, natural alternatives are being evaluated (141). Plant derived polyphenols and their
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associated health benefits as antimicrobials against bacteria are well established (142-145). In
addition, there is an increasing demand from the consumers and the industry for natural
alternates to synthetic chemical additives used in food systems. Extensive research on potential
plant polyphenolic extracts, as natural antimicrobials are ongoing. Below are some of the widely
used and studied natural plant extracts for their antimicrobial (and if known antiviral properties)
and other health beneficial properties.

Blueberry polyphenols
Blueberries (genus Vaccinium) are perennial flowering plants native to North America.
Blueberries are a rich source of polyphenols including anthocyanins, flavonoids and
proanthocyanidins (PAC), also referred to as condensed tannins (1). Tannins (condensed and
hydrolysable) differ from other phenolic compounds for they are able to precipitate proteins,
known as astringency (146). Proanthocyanidins (PAC’s) are dimers, oligomers, and polymers of
catechins bound together by links between C4 and C8 (or C6) where the monomeric flavanols
differ in the stereochemistry of C-3 and their hydroxylation pattern in ring A and B (147).
Blueberries have been known to contain around 88-261 mg of proanthocyanidin/100 gram of
edible portion as per the USDA, 2004 database for flavonoid content. Being a source of natural
anthocyanin and proanthocyanidins, blueberries are known to have a broad spectrum of
biomedical benefits such as treatment/prevention of cardiovascular disorders, advancing ageinduced oxidative stress, inflammatory responses, and diverse degenerative diseases along with
anticarcinogenic, neuroprotective, cardioprotective and antimicrobial properties (148).
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Antibacterial properties:

Berry ellagitannins are known to possess strong antimicrobial

properties including prevention of adherence and colonization of bacteria (149). Blueberries
contain polyphenols including anthocyanins and flavonoids and proanthocyanidins (PAC), also
referred to as condensed tannins (1) are known to have antimicrobial activity against Listeria
monocytogenes, Helicobacter pylori, Salmonella Typhimurium, Escherichia coli and Candida
albicans (143, 150, 151). Salmonella Enteritidis and Listeria monocytogenes. S. Enteritidis was
shown to be reduced by 5.85 log CFU/ml after 24 h and L. monocytogenes by 7.64 log CFU/ml
after 24 h by 24 ppm of blueberry water extracts. Similar reduction of 5.50 log CFU/ml and 6.52
log CFU/ml was observed for S. Enteritidis and L. monocytogenes with blueberry ethanol extract
after 24h (152). This data suggests that blueberry extracts can be used as antimicrobial agents in
various food products as additives or consumed for treating infections arising from both Listeria
and Salmonella species (152). Blueberry and cranberry contain two compounds (fructose and a
high molecular weight polymeric compound) that inhibit adhesin, (required for the bacteria to
adhere) thereby preventing attachment of pathogenic Escherichia coli to mucosal cells of the
urinary bladder (151). Blueberry fractions that had concentrations of 8.9 g/L GAE for total
blueberry extract, 8.0 g/L GAE for monomeric phenolics, 173.08 mg/L C3G for anthocyanins
and proanthocyanidins, 139.8 mg/L C3G for anthocyanins, and 1.0 mM PA2 for
proanthocyanidins was shown to cause 8 log CFU/ml reduction in growth of L. monocytogenes
for all tested concentrations ranging from 0-4.45 g/L (gallic acid) and 0-86.54 g/L (cyaniding-3glucoside) while E. coli O157:H7 demonstrated an 8-log CFU/ml reduction in growth for all
fractions at their highest concentrations (143). S. Typhimurium demonstrated similar log
reductions in growth to E. coli O157:H7, except for being more susceptible to monomeric
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phenolics and anthocyanins and less susceptible to proanthocyanidins (143). Signiﬁcant
inhibition of about 50% of Helicobacter pylori (causative agent of ulcers) was demonstrated with
elderberry (30%), bilberry (50%), blueberry (50.5%) and OptiBerry (62%) extracts. Addition of
clarithromycin to the 0.25% berry concentrations, led to a signiﬁcant increase (about 70%) in the
bactericidal effects of the elderberry, bilberry, blueberry and OptiBerry extracts compared with
the berry extracts alone. Addition of 1% clarithromycin led to more than 90% of inhibition of H.
pylori for all berry extracts (150). Another study with blueberry extracts at 25-50% w/w in
combination with an antibiotic such as trimethoprim at about 0.001% to 10% was found to
enhance its antimicrobial activity against attachment and subsequent biofilm formation of
urinary tract infections causing organisms E. coli and C. albicans (153). Mechanism of
antibacterial action: The outer bacterial membrane of bacteria provides the fundamental barrier
against any damage. Blueberry phenolics are known to have profound effects on membrane
fluidity, inhibition of extracellular microbial enzymes, changing the fatty acid profile, and
disrupting metabolism disruption (154). Proanthocyanidins from blueberry (0.15 g/L Gallic acid
equivalent), were shown to increase membrane permeability in E. coli O157:H7 (155).
Antiviral properties: Only a few studies are reported in literature on the effects of blueberry
extracts against viruses. The methanol extract fraction of blueberry leaves (proanthocyanidin
more specifically epicatechin) was shown to inhibit hepatitis C virus (HCV) subgenome
expression by binding to nuclear ribonucleoprotein A2/B1 that plays an indispensable role for
HCV subgenome expression in replicon cells (156). The purified proanthocyanidin from
blueberry leaf extracts was also found to suppress the expression of NS-3 (non-structural gene-3)
protein gene in HCV (156). Similarly hydrolysable and galloylated tannins (0.03-0.1
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microgram/ml) were shown to inhibit herpes simplex virus adsorption to its host, African green
monkey kidney cells and human adenocarcinoma cells (157). Another study evaluated the
influence of blueberry juice on the survival of human NoV surrogates (FCV-F9, MNV-1, and
MS2) at refrigeration temperatures over 21 days, where FCV-F9 was shown to be completely
reduced in BJ at 4°C after 1 day. MNV-1 showed minimal reduction on 14 days, and MS-2
complete reduction after 7 days (2).
Antigiardial properties: Trophozoites of Giardia duodenalis, a human intestinal parasite, were
inhibited by blueberry polyphenols and other berry fruits like strawberry, blackberry, cloudberry
at 166µg gallic acid equivalents. Incubation of G. duodenalis trophozoites in extracts of
blueberries were also shown to cause their distortion, swelling, blebbing, flagellar truncation and
increased killing, and increased the rate of spontaneous excystation of C. parvum oocysts (158).
Antioxidant properties: In blueberries, primarily anthocyanins along with hydroxycinnamates
such as chlorogenic acid contribute to antioxidant properties (149). Studies have shown that
blueberries help maintain healthy blood flow via several mechanisms including healthy lowdensity lipoprotein (LDL) oxidation, normal platelet aggregation, and maintenance of endothelial
function (1, 159, 160). Fresh mature fruits of rabbiteye blueberry when assayed for their
antioxidant properties were found to have the strongest antioxidant capacity, and the highest TPC
(Total phenolic content; 9.44 mg gallic acid/g DW), TFC (Total flavonoid content; 36.08 mg
rutin/g DW), and TAC (Total anthocyanin content; 24.38 mg catechin/g DW) values among
other berries like blackberry and strawberry (1). These antioxidant properties are considered to
be associated with phenolic acids, catechins (flavanols), and proanthocyanidins (condensed
tannins) (1). In one study, a drink made form wild blue berries (containing approximately 375
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mg of anthocyanins) was tested for its antioxidant potential in human volunteers for reducing
oxidative stress and inflammation. After 6 weeks of consumption, significant reduction in levels
of oxidized DNA was reported (161). Thus, blueberry juice consumption could be beneficial in
relieving oxidative stress caused during chronic liver diseases.

Anti-diabetic: With increased incidences of diabetes worldwide, there is a need to search for
alternatives to complement the currently available therapies. Blueberries with a wide range of
health benefits and high amount of polyphenols are good candidates to screen for antidiabetic
properties. Diabetes control approaches include reducing hyperglycemia through inhibition of
carbohydrate hydrolyzing enzymes such as α -glucosidase. A study showed that phenolics from
blueberry flowers had strong α -glucosidase inhibitory activity (162). Another study showed
similar findings where anthocyanins and proanthocyanidins from fermented blueberry blackberry
beverages were found to be inhibitors of carbohydrate-utilizing enzymes and inhibitors of
inﬂammation (163). These studies show that consuming blueberries or their fermented beverages
might be beneficial towards control of diabetes and inflammation. Blueberries have been shown
to control diabetes by improving insulin sensitivity. When a cobiotic of inulin and sugar free
blueberry pomace extract and oat was administered to a Type II diabetic patient for 8 weeks
along with metformin (initial treatment for Type II diabetes), the blood sugar was shown to
lower to 100mg/dL and weight loss of 5.5kg was reported. Such studies could lead into use of
supplements from natural sources with anti diabetic properties to escalate the effect of commonly
used drugs and reduce side effects (164).
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Anticarcinogenic Effects: Cancer is a leading cause of death and accounted for 7.6 million
deaths (around 13% of all deaths) in 2008. Polyphenols have been reported to have effects of on
cancer cells by affecting growth, differentiation and apoptosis (165). Some of the studies below
have attempted to investigate the anticancer properties associated with blueberries and its
consumption. When blueberry anthocyanin extracts were tested for anticancer potential against
two breast cancer cell lines (MDA-MB-231 and MCF7) at 250 μg/ml was found to have a
significant effect (65%) in reducing cell proliferation after 24 h of cell incubation (166).
Anticarcinogenic effects of blueberry phenolics against breast cancer were recently demonstrated
in a study (167), where rats on 5% blueberry diet (containing 38 mg/g of total phenolics and 21
mg/g of total anthocyanins) in chemopreventive and therapeutic modes were shown to have
delayed tumor development by 28 and 35 days respectively to 17β-estradiol induced breast
cancer. Additionally, 96% animals in a control group were shown to develop palpable mammary
tumors compared to 60% and 55% animals in chemopreventive and therapeutic groups
respectively (167). The study suggests anticancer and protective role of blueberries by regulating
tumor development.
Cardioprotective effects: Cardio protective effects of blueberry extracts and its components are
being extensively studied. Effects of blueberry supplementation in diets on metabolic syndrome,
lipid peroxidation and inflammation were evaluated in obese men and women (168). After 8
weeks of dietary blueberry supplementation (50 g freeze-dried blueberries; 350 g fresh
blueberries), a significant decrease of about 4.5% and 2.8% higher decrease in systolic and
diastolic blood pressure were reported as compared to control groups. This study suggests that
including blueberry as a dietary supplement might help in reducing the risk factors related to
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cardiovascular disorders and reducing the intensity by a certain extent (168). Hypertensive rats
on 2% w/w blueberry enriched diet for 6 to 12 weeks were reported to have lower blood
pressure, improved glomerular filtration rate, and decreased renovascular resistance as compared
to control groups. Long-term blueberry diet also showed significant decrease in total reactive
oxygen species (ROS), peroxynitrite, and superoxide production rates kidney tissues (169). The
results suggest that including blueberries in diet could prove beneficial for individuals suffering
from hypertension.
Antiobesity: Obesity and its prevalence has increased significantly over the last few decades
with the consumption of high fat diet and lack of exercise and sedentary lifestyle. Polyphenols
present in green tea, grape seeds, orange, grapefruit and berries are known to have anti obesity
effects (170). Antiobesity effects of blueberry juice were recently demonstrated in mice on a
high fat diet (171). Four-week-old C57BL/6 mice were fed a high-fat diet (HFD) with or
without blueberry juice for 12 weeks. Consumption of blueberry juice was shown to reduce the
body weight of the mice by 7.3%. Liver lipids were reported to be ~ 10mg/ml lower in levels in
blueberry juice fed rats as compared to HFD controls. Thus consumption of blueberry juice
could
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blueberry polyphenols at concentrations of 150, 200, and 250 μg/mL led to a reduction of 27%,
63%, and 74% in intracellular lipid content respectively as compared to the control. All three
concentrations of blueberry polyphenols were also reported to have significant inhibition of cell
proliferation(170).
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Bioavailability and delivery: Pastes, gel, powders can be potential delivery methods for
targeting gastrointestinal conditions. Insuring bioavailability for any potential application is also
an important consideration. Bioavailability of anthocyanins has been reported to be very low in
human volunteers. A study carried out showed that when doses of 150 mg to 2 g total
anthocyanins were given to the volunteers in the form of berries, berry extracts, or concentrates,
levels of anthocyanins in plasma detected thereafter were reported to be as low as 10–50 nmol/L
(172). Thus there is a need to develop effective delivery systems to ensure the delivery of
bioactives.

Antioxidant capabilities of blueberry and cranberry were investigated under

simulated conditions of GI tract were demonstrated, where berry homogenates first exposed to
digestive enzymes and then exposed to CaCo-2 cells did not show significant reduction in the
antioxidant activity (173). Also, these treated homogenates were shown to annul the effects of
ROS (reactive oxygen species) generated by hydrogen peroxide (173). Such critical evaluations
are necessary to develop better delivery methods to the gut by way of encapsulation or controlled
release so as to protect the beneficial properties from the gut enzymes and acids. More studies
need to be carried out to validate its safety via feeding studies and clinical trials.
Grape seed extract
Grapes (genus Vitis) are native to southern Europe and Western Asia near the Caspian
Sea, and were brought to North America and Europe. The medicinal and nutritional properties of
grapes have been well known over centuries, where Egyptians and Greeks used the various
forms of grapes (ripe, unripe, dried) in healing of various health conditions. Grape seed extract
(GSE) is a natural by-product of the wine and grape juice processing industries (174). Grape seed
and grape skin has been shown to contain bioactive components such as flavonoids, polyphenols,
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anthocyanins, proanthocyanidins, procyanidins, and the stilbene derivative, resveratrol (175).
Grape seeds are also known to have high amounts of monomeric phenolic compounds, such as
epicatechin,

epicatechin-3-O-gallate,

catechins,

and

dimeric,

trimeric

and

tetrameric

procyanidins (176). Several pharmacological and therapeutic benefits such as antimicrobial, antiinflammatory, antioxidative, cardioprotective, and neuroprotective effects have been reported to
be associated with GSE (177). GSE has been approved as a generally recognized as safe (GRAS)
by the U.S. Food and Drug Administration and hence is being studied extensively for its use as
an antimicrobial agent in foods. ("GRAS" is Generally Recognized As Safe under sections
201(s) and 409 of the Federal Food, Drug, and Cosmetic Act) (178). GSE at doses of 50 to 100
mg/ml per day do not exhibit toxicity or adverse health effects in rats (176, 179, 180). This adds
advantages to GSE that has great potential for use as a value-added product associated with its
low cost, sustainability, and lack of evidence of being hazardous to the environment.
Antibacterial effects of GSE: GSE (both methanol and acetone extracts) were found to be more
effective against Gram-positive bacteria when compared to Gram-negative bacteria, when tested
against several foodborne bacterial pathogens (175).The minimum inhibitory concentration
(MIC) with a methanol:water:acetic acid (90:9.5:0.5) extract was found to be 900 ppm for the
gram-positive Bacillus cereus, Bacillus subtilis and Bacillus coagulans and 1000 ppm for
Staphylococcus aureus (175).For the gram-negative Escherichia coli and Pseudomonas
aeruginosa, the MIC was found to be 1250 and 1500 ppm, respectively. When the extract
contained acetone (acetone: water: acetic acid (90:9.5:0.5)) instead of methanol, differences in
MIC were observed for the gram-positive bacilli, resulting in MICs of 850 ppm for B. cereus, B.
subtilis and B. coagulans, while the other organisms showed similar MICs to the methanol:
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water: acetic acid (90:9.5:0.5) extract. These researchers determined that gallic acid was the
bioactive component, with the three hydroxyl responsible for the antibacterial activity of GSE
(175). Muscadine grape skin extracts were also found to be effective against Helicobacter pylori
(causative agent of ulcers) with MIC ranging from 256 to 512 g/ml, and the MIC ranged between
256 to 1,024 g/ml for muscadine seeds (181). Resveratrol and ellagic acid were also found to
inhibit this ulcer causing bacteria, with an MIC range of 6.25 to 50 g/ml, while myricetin was
found to have no effect (181). GSE at a concentration of 5 mg/ml was also found to inhibit the
dihydrofolatereductase activity and growth of S. aureus at 0.5 mg/ml after 6 h, however some
injured cells were recovered after 12 h (182). For GSE at 1 mg/ml, these researchers reported
99% of inhibition after 24 h, with no observed cell recovery.
In another study, commercial grape juice and skin and grape seed extract were tested
against the gram-positive foodborne pathogen, Listeria monocytogenes, of concern to
immunocompromised individuals and pregnant women. Commercial grape juice decreased L.
monocytogenes from 106 –107 CFU/ml to undetectable levels and B. cereus by 1-log within 10
min in the juice, without further reduction after 60 min (183). The seed and skin extracts (250–
280 mg/L gallic acid) were reported to have similar anti-listerial activity to that of the
commercial grape juice (183). Anti-bacterial activity of GSE was also tested against methicillin
resistant S. aureus (MRSA), which is an on-going problem in nosocomial and other related
infections, where health-care providers continue to have challenges in prescribing appropriate
antibiotics against these infections (184). All of the 43 MRSA strains tested were found to be
inactivated at 20.67 µg of GSE flavonoids (184). Another study showed that GSE at 1 and 5
mg/mL was found to be effective against MRSA strains resulting in a 2.9-4.0 log CFU/ml
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reduction after 2 h at 37°C (145). These results suggest that natural products such as GSE can be
used as effective antimicrobials for multidrug resistant strains as an alternative to regular
antibiotics. Red GSE at 0.5 mg/ml was found to reduce plaque formation of Streptococcus
mutans in vitro by 40% as compared to control (185), showing the potential of GSE to prevent
dental caries.

Antiparasitic effects of GSE: GSE has been reported to have antiparasitic effects against
Histomonas meleagridis, a protozoan parasite responsible for histomonosis with high mortality
in turkey and chicken (186); Blastocystis, a prevalent unicellular parasite in human fecal
specimens (187); Trichomonas gallinae that causes avian trichomonosis in various bird species,
especially pigeons and doves (188); and Trichostrongylus colubriformisa parasite of herbivorous
mammals (189). GSE at 100 ppm for 6-12 h was shown to kill 50% of exposed Lymneacailliaudi
snails (LC50; lethal concentration 50) with higher molluscidal activity with increased exposure
time to 12-24 h (190). However GSE showed weak effect against Culex pipiens larvae
(responsible vectors for malaria, dengue and yellow fever) where their mortality did not increase
over 50% even after increasing the GSE concentration to more than 200 ppm for 48h (190). GSE
at 5 mg/ml was also found to completely inhibit (initial number of 103 histomonads) the growth
of Histomonas meleagridis, Trichomonas gallinarum and Blastocystis sp. after 24 and 48 h
(191). Another study tested a new product containing GSE against the avian parasite H.
meleagridis, that showed inhibition of its growth at concentration of 2.5 or 5 µl/ml after 48 h
(192). GSE at 10-20 mg/kg was reported to reduce mortality in chickens infected with Eimeria
tenella and also alleviated the oxidative stress following infection and helped improve the weight
29

gain of chickens which is important for the poultry industry (193). Flavan-3-ols and galloyl
derivatives of condensed tannins that are components of GSE were found to be completely
inhibitory towards egg hatching of Trichostrongylus colubriformis at 1000 mg/ml, and
epigallocatechin gallate at 100 mg/ml showed 100% inhibition of T. colubriformis larval
development (194). Methanol extracts of grape seed at 300 and 600 mg were reported to be
effective in killing the immature form of the leech Limnatis nilotica within 260 and 200 min,
respectively, but was not effective towards the mature forms, suggesting that GSE should be
used in combination with other treatments to boost their anti-leech effects (195).
Antiviral activity of GSE: In addition to bacteria, GSE is known to have effects against several
viruses of human health concern. Human noroviruses are recognized as leading causes of nonbacterial gastroenteritis worldwide (3, 196). However, since these non-enveloped single-stranded
RNA containing human noroviruses cannot be cultivated in the lab, cultivable surrogates such as
feline calicivirus (FCV-F9) and murine norovirus (MNV-1) are used to determine inactivation by
various chemical or processing technologies (197). Hepatitis A virus is another non-enveloped
single-stranded RNA containing foodborne virus important because of the severity of the disease
that affects the liver and lasts for more than a month. GSE at 0.25, 0.5, and 1.0 mg/ml for 2 h at
37°C was shown to reduce FCV-F9 titers by 3.64, 4.10, and 4.61 log PFU/ml; MNV-1 by 0.82,
1.35, and 1.73 log PFU/ml; and HAV by 1.81, 2.66, and 3.20 log PFU/ml (197). GSE was also
shown to prevent replication of human norovirus surrogates using ELISA studies that were in
agreement with the earlier studies of Su et al., 2011, where MNV-1 titers were shown to be
reduced by 3 log PFU/ml when treated with 0.2 mg/ml (144). GSE was also evaluated for its
anti-noroviral activity as a surface disinfectant by these researchers, where 0.2 mg GSE/ml,
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showed a reduction of MNV-1 to undetectable levels without the presence of any protein load. In
presence of 0.01% dried milk, reduction to undetectable levels was obtained only with 2 mg/ml
GSE, while in tap water, GSE at 0.2 and 2 mg/ml was shown to cause 1 and 2 log PFU/ml
reduction in MNV-1 titers (144). The effect of the symptoms of HIV-1 and AIDS is well
publicized, emphasizing the need for improved control and preventive measures, where GSE
may play an important role. GSE is also reported to interfere with the binding of the AIDS
causing human-immunodeficiency virus (HIV-1) to its host cell receptor and thus prevents HIV1 entry into the normal lymphocyte (198).
Mechanism of action of GSE against microbial pathogens: With regards to antibacterial
properties of GSE, the bacterial cell membrane being semipermeable allows the entry of
polyphenols that can interact with the cytoplasm or cellular proteins, with higher ability of GSE
polyphenols (that are present in undissociated forms) to enter the cell and interact with cellular
components (199). Thus, the benefits of the antimicrobial properties of GSE can be exploited for
food or clinical applications. GSE was shown to have some effect on viral adsorption of FCVF9, MNV-1, and HAV, with less effect on replication (197). These researchers showed that when
the respective host cells were treated with GSE before viral infection, the titers of FCV-F9,
MNV-1, and HAV were decreased by 0.8, 0.5, and 1.9 log PFU/ml, respectively. GSE treatment
after the viral infection of the host cells showed a 0.1, 0.2, and 0.8 log PFU/ml reduction,
respectively. The higher reduction obtained by GSE when used in pre-infection than postinfection, indicated that GSE either blocks virus binding to the host cell receptors or coats the
virus to prevent attaching to the host-cell or causes clumping of viral particles. GSE has also
been shown to inhibit the replication and expression of HIV-1, an enveloped virus with
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glycoproteins gp 120 and gp41, by blocking binding of HIV-1 to the cell receptor and preventing
HIV-1 entry into the normal lymphocyte (198). The study also showed that GSE at
concentrations of 0.5 to 5 mg/ml over 24 h at 37°C was found to significantly down regulate
expression of HIV-1 co-receptors, CCR2b and CCR3 (B- chemokine receptors), in peripheral
blood mononuclear cells (198).
Resveratrol (RV) is a non-ﬂavonoid polyphenol found in grape seed and grape skin and is
known to be synthesized in response to external stimuli and injury (200). RV has been known to
affect several intracellular signaling pathways, and strongly inhibits the in vitro and in vivo
replication of inﬂuenza virus (201). Virus replication was reportedly reduced by 20 μg/mL of RV
and completely inhibited by 40 μg/mL of RV over 72 h of infection time. RV at 20 µM was also
found to inhibit the replication of polyomavirus, with complete reduction of replication after 24 h
of infection (202). Polyomaviruses are small, double stranded DNA viruses known to occur in
immunocompromised individuals and may cause hemorrhagic cystitis in recipients of bone
marrow transplantation and progressive multifocal leukoencephalopathy (203).
Studies were also carried out to gain insight about the mechanism of action of GSE and
its components against bacterial pathogens, and it was proposed that the antibacterial activity of
tannins could be due to the inhibition of extracellular microbial enzymes (146). Inhibitory effects
of GSE could also be attributed to the constituent phenolic compounds that can form phenoxyl
radicals upon entering the cell, or binding to the cellular membrane and causing cellular
disruption (204). In addition, scanning electron microscopy studies carried out on MRSA cells
treated with GSE showed the that the cell surface was rough and disrupted in comparison to the
smooth and rounded surfaces of control cells (145). This suggests that GSE may be acting by
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disrupting the bacterial cell membrane causing leakage of cellular material and thereby
inactivation. In addition to the antimicrobial properties of GSE, research on other health benefits
is also being carried out extensively.
Role of GSE in Anti-inflammation: Inflammation is theorized to be the underlying cause of
most health issues and chronic inflammation has been linked to heart disease, hay fever,
rheumatoid arthritis, obesity, and diabetes (205-208). When the anti-inflammatory and
antioxidant properties of GSE were investigated in the case of septic shock caused by the
intraperitoneal injection of lipopolysaccharide (LPS) derived from Escherichia coli, GSE at
doses of 75 mg/kg/day had anti-inflammatory effects by decreasing the nitrate and nitrite (NOx)
levels in the plasma, red blood cells, spleen, and liver (209). These researchers showed that high
doses of 200 mg/kg/day could down regulate the genes Il-6 (interleukin 6) and iNos (inducible
nitric oxide synthase) associated with inflammatory responses against the LPS endotoxin (209).
Murine studies showed that when GSE at 100 mg/kg was administered to acute asthmatic mice,
there was a decrease in number of eosinophils, airway inflammation, hyper responsiveness, and
oxidative stress (210).
GSE and its effects on Atherosclerosis and Heart Disease: GSE has been widely studied for
their cardio-protective properties, and in reducing cholesterol and plasma lipoproteins. For
example, GSE was shown to alleviate the side effects such as cardiac steatosis (adipose
degeneration) and lipotoxicity in rats fed on a high fat diet for 45 days at levels of 500
mg/kg/bodyweight (211). GSE at doses of 50 and 100 mg GSE/kg body weight were found to
reduce 49 and 63% foam cells, a biomarker of early stage atherosclerosis (212). Red grape seed
extract at 200 mg/day for 8 weeks was found to reduce total cholesterol and oxidized low-density
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lipoprotein particles by 10.68 mg/dL and 5.47 mg/dL, respectively (213). Thus, GSE
consumption may also prove to be beneficial in reducing the risk of atherosclerosis (213).
Additionally, dry GSE at a concentration of 100 mg was found to significantly decrease the
amount of serum cholesterol levels in human volunteers (214). Taken together, these studies
show the anti-atherosclerotic and cardio-protective effects of GSE.
GSE and its role in obesity and diabetes: GSE has also been explored for use in controlling
obesity and preventing diabetes. Lipoprotein lipase (LPL) is an enzyme involved in hydrolysis
of triacylglycerol by releasing free fatty acids for uptake into adipocytes, involved in obesity.
GSE at 1 mg/ml was found to inhibit human pancreatic lipase activity by almost 80% within 5
min of incubation in adipocytes, suggesting the benefits of GSE against obesity (215). GSE was
also found to up-regulate Tregs (regulatory T cells) and T helper 2 cytokine producing cells that
play a role in suppressing excessive immune responses (216).
GSE was also shown to reduce postprandial plasma glucose in healthy individuals, where the
plasma glucose concentrations at 15 min and 30 min after consumption of a high carbohydrate
meal with 100 mg or 300 mg of GSE was significantly lower than that of a high carbohydrate
meal without GSE (217). The study proposed the use of GSE as a preventive measure against
diabetes in otherwise healthy populations. Mice on a high fat diet were shown to be protected
from nerve fiber loss compared to controls when administered 100 mg/ml GSE for 12 weeks,
suggesting that GSE may provide benefits towards the treatment of diabetic neuropathy (218).
Antioxidative effects of GSE: GSE is known to be an efficient antioxidant and free radical
scavenger (175). GSE at 50 mg/l was shown to be an effective radical scavenger, being better
than vitamins C and E (219). GSE components like procyanidin B4, catechins, and gallic acid at
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concentrations of 10-25μmol/l were reported to be good preventive agents against cellular DNA
oxidative damage, though, these compounds may induce cellular DNA damage at higher
concentrations of 150 μmol/l (220). GSE at 2 mg/ml was found to inhibit the peroxidation of
polyunsaturated fatty acids induced by UV–C (221).
Anticarcinogenic effects of GSE: When grape seed polyphenols were investigated for their
anti-carcinogenic effects towards 12-O-tetradecanoylphorbol-13-acetate-(TPA)-induced tumor
reduction as a topical application, tumor incidence was inhibited by 35 and 60%, tumor
multiplicity was inhibited by 61 and 83% and tumor volume was inhibited by 67 and 87% at
concentrations of 0.5 and 1.5 mg/ml/mouse/application on mouse skin (222). More recently in
breast cancer studies, GSE at 100 μg/ml was found to increase apoptotic cell death signiﬁcantly
by up to 12% after 72 h incubation, when the highly metastatic MDA-MB 231 breast cancer line
was used (223). Grape powder, resveratrol, and GSE when administered topically 30 min after
7,12-dimethylbenz [a] anthracene (DMBA, a skin carcinogen) exposure at concentrations of 1, 2,
or 4 mg was shown to inhibit epidermal hyperplasia, proliferation, and dermal inﬂammation
(224). GSE at 50 μg/mL was also reported to significantly induce apoptotic death in non-smallcell lung cancer cell lines by causing a release of cytochrome c in the cytosol and cleavage of
caspases 3 and 9 that play a role in cell death (225).
Potential application of GSE for food industry as produce wash: Natural products that are
cost-effective, environmentally friendly, and sustainable are of great interest to the food industry.
GSE is one such natural product, which is being investigated as an antimicrobial surface
disinfectant. Several studies have aimed to evaluate the potential of GSE for its use as a food
additive or a pre-packaging wash or treatment. Kao et al., 2011 used pork slices as a “model”
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food to evaluate its use in the food industry. Pork slices were first immersed in 20 mg/ml, 60
mg/ml, or 100 mg/ml of GSE solutions and then inoculated with S. aureus suspensions, and
incubated at 37°C for 8 h and 24 h, after which >99% of inhibition was observed for pork slices
treated with 100 mg/ml GSE (182). However, with such high concentrations of GSE used (due to
its bitter taste), it is important to note that there may be issues with sensory acceptance of these
products by consumers. In another study by Corrales et al., 2009, GSE was introduced into pea
starch films at a concentration of 1% that showed growth inhibition of Brochothrix
thermosphacta (spoilage organism) by 1.3 log CFU/mL in pork loins during the first 4 days of
incubation (226). When GSE (commercially available Gravinol-S) was tested as an antimicrobial
wash on fresh produce, MICs for Listeria monocytogenes and L. innocua ATCC 33090 were
found to be 50 and 78 µg/ml (227). When tested against live cells using flow cytometry at subMICs for 2 min, GSE was found to cause rapid permeabilization and clumping of L. innocua.
GSE treatment of 1250 µg/ ml was shown to yield the highest reduction of L. monocytogenes by
2 log CFU/ml after 2 min on spiked Roma tomatoes. These results suggest the potential
application of GSE as a surface disinfectant for fresh produce (227). Conventional and
electrostatic spraying of malic acid (MA), tartaric acid, gallic acid and GSE against Salmonella
Typhimurium using spinach as a model system, showed that MA alone sprayed electrostatically
caused reductions of 1.6 and 3.2 log CFU/g after 7 and 14 days, while GSE alone led to a
reduction of 0 to 1.4 log CFU/g (228). These researchers reported that maximum reduction of 2.6
to 3.3 log CFU/g was observed for spinach leaves treated with 2% malic acid in combination
with 3% GSE when sprayed electrostatically, while lower log reductions were observed (0 to 1.5
log CFU/g) when sprayed conventionally (228). These results showed that electrostatic
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combination sprays containing MA and GSE were more effective in reducing the foodborne
gram-negative S. Typhimurium that is linked to on-going produce outbreaks.
Consumer concerns regarding addition of nitrite in processed meats has led to finding
natural alternatives such as GSE (142). GSE at 0.5% was found to reduce L. monocytogenes by
1.1 log CFU/g after 9 days at 10oC in cured meats (142). When fresh pork slices that were first
treated with GSE along with oregano, clove and pomegranate and then inoculated with low (10
CFU/m1) and high (105 CFU/mL) titers of L. monocytogenes, S. aureus and S. enterica,
aerobically packed and stored at 20OC, the treated samples showed reductions of 1.36, 0.96 and
1.75 log CFU/g for L. monocytogenes, S. aureus, and S. enterica, respectively after 9 days (179).
Irradiated meat samples when treated with a single 1% GSE treatment led to a reduction
from of 6.5 to 4.5 log CFU/ml L. monocytogenes in 12 to 18 h but no subsequent further
reduction were observed; while nisin (6400 IU/ml) treatment gave an initial reduction of 3 log
CFU/ml in 12 h though the cell numbers rebounded after 18 to 24 h (180). However, these
researchers showed that the combined treatment with 1% GSE and nisin (6400) IU led to
reduction below detectable limits (180).
Application of GSE as an antiviral produce wash was also studied where 0.25 to 1 mg/ml GSE
was found to reduce FCV-F9 and MNV-1 titers within 5 min on spiked lettuce and peppers
(229). High titers (~7 log PFU/ml) of FCV-F9 on lettuce and peppers were found to be reduced
by 2.71 log PFU and 3.05 with GSE at 1 mg/ml after 1 min, respectively, while MNV-1 was
shown to be reduced by 0.2-0.3 log PFU on lettuce and 0.8 log PFU on peppers for low titers (~5
log PFU/ml) (229).
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Pomegranate polyphenols
Pomegranate (Punica granatum) is a plant native to Iran, India, and the Mediterranean countries
such as Turkey, Egypt, Tunisia, Spain, and Morocco (230). Pomegranate juice and its peel are
known to be a rich source of polyphenols including flavonoids (anthocyanins, catechins and
other complex flavonoids) and hydrolyzable tannins (punicalin, pedunculagin, punicalagin, gallic
and ellagic acid), which account for 92% of the antioxidant activity associated with the fruit
(231). Among these, Ellagitannins and punicalagins were reported to be the main bioactive
fractions in pomegranate (232). The anthocyanin content in pomegranate juice was shown to be
around 135 mg/L; punicalagins and punicalins content were shown to be between 80 and
135 mg/L (233). In addition, it is also known to contain organic acids such as ascorbic acid, citric
acid, fumaric acid, and malic acid (230).Methanolic extract of pomegranate was shown to inhibit
the formation of biofilms by S. aureus, methicillin resistant S. aureus, Escherichia coli, and
Candida albicans where the reported MIC was 1000µg/ml (234). The extract also disrupted preformed biofilms of C. albicans. Pomegranate extracts were also examined for their antimicrobial
effects against Clostridium difficile, where the effective minimum inhibitory concentration
ranged in between 12 to 25 mg/ml gallic acid equivalent (235). Aqueous pomegranate extracts
were demonstrated to have activity against E. coli O157:H7 with an MIC of 0.19 mg/mL (236).
Studies have proposed that the mode of action of pomegranate polyphenols is by disrupting the
cellular membranes, inhibiting microbial enzymes and through interaction with proteins and coaggregation of microorganisms (237, 238). Pomegranate extract was shown to have antifungal
properties, where the crude extract at 5 mg/ml inhibited Stemphylium botryosum spore
germination by 74% (232). Effect of purified pomegranate extract on influenza virus was studied
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where punicalin (tannin) was shown to inhibit the virus replication and also inhibited
agglutination of chicken red blood cells by the virus, and, when used in combination with the
antiviral oseltamivir (237). Pomegranate polyphenol powder extract at 800 µg/ml was shown to
reduce influenza virus titers by 3 log at room temperature within 5 min and it was suggested that
this antiviral activity could be owing to the coating of the virus (239). In addition, pomegranate
polyphenols were also shown to inhibit replication of Human immunodeficiency virus (HIV-1)
by blocking the virus binding to CD4 host cell receptors (240).
Pomegranate juice was demonstrated to reduce titers of human norovirus surrogates; FCV-F9,
MNV-1, and MS2 by 1.20, 0.06, and 0.63 log PFU/mL respectively at room temperature after 1h
(241). When treated with polyphenols from pomegranate a reduction of 1.30, 2.11, 3.61
logPFU/mL for MNV-1 was obtained with 8, 16, and 32 mg/mL within 1h at room temperature.
Titers of FCV-F9 were reduced to undetectable levels with 8 mg/ml within 1h at room
temperature. The study suggested that this antiviral effect could be due to the possible binding of
the polyphenols to the virus particle or by blocking host cell receptors (241).
Cranberry polyphenols
Cranberries (Vaccinium macrocarpon) are native to North American region and contains diverse
group of phytochemicals, including flavonoids, hydroxycinnamic acid derivatives, organic acids,
and isoprenoids including ursolic acid and lutein(242). The predominant bioactive compounds
found in cranberries are the flavonols, the flavan-3-ols, the anthocyanins, the tannins
(ellagitannins and proanthocyanidins), and the phenolic acid derivatives. The average flavonol
content in cranberry is 410mg/100 g fresh fruit weight (243). Cranberries have a high amount of
oligomeric and polymeric pigments, also referred to as condensed non-hydrolyzable tannins or
39

proanthocyanidins (PAC). 51-90% of the PAC’s in cranberries are A-type PAC’s. A-type
PAC’shave anti-adhesion activity against the urinary tract infection causing P-fimbriated E. coli
to uroepithelial cells and decrease in the expression of P-fimbrial gene (244). Commercial
cranberry juice (CJ, pH 2.5) was found to reduce common gastrointestinal bacterial pathogens,
E. coli O157:H7 and L. monocytogenes at 8 log CFU to undetectable levels after 15 min and 1 h
of treatment at -23oC (storage conditions) respectively. Cranberry proanthocyanidins (CPACs) at
25 mg/ml were found to inhibit infection and invasion of epithelial cells by enteropathogenic
Escherichia coli (EPEC) and Salmonella Typhimurium by preventing the formation of actin
pedestal required by EPEC for host infection (245). CJ was also found to inhibit biofilm
formation of E. coli, L. monocytogenes, Campylobacter jejuni, S. Typhimurium and S. aureus. It
was shown that CJ reduced the non-specific adhesion of bacterial cells to borosilicate glass
(246). Oregano–cranberry (50:50) extracts at a concentration of 750 ppm in combination with
2% sodium lactate were shown to inhibit growth of L. monocytogenes by 1 log CFU/ ml in
cooked ground beef samples. It was reported that in presence of 1mM proline, the effect of
Oregano–cranberry with sodium lactate was significantly reduced indicating proline
dehydrogenase to be the likely site of action for phenolic phytochemicals and lactate radical
(247). In a similar study, cranberry juice was shown to reduce aerobic plate count for coliforms
initial ~7 log CFU/ cm2 to 3.86 CFU/cm2 on chicken breasts (248). Studies on anti-adhesive
effect of cranberry PAC on E. coli to uroepithelial cells showed that stationary phase strains was
found to be about 52% and 75.5% inhibited in the presence of 100 μg/ml cranberry PAC A2 in
pretreated uroepithelial cells (249). Cranberry proanthocyanidins (CPAC) at 1 mg/ml were also
shown to reduce methicillin resistant Staphylococcus aureus (MRSA) ATCC 33591 by 1.04,
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1.68 and 1.84 log10 CFU/ ml after 1, 2 and 8 hours of treatment respectively. Complete
reduction was shown after 24 hours at 370C, however MRSA ATCC 33593 was reported to
reduce completely within 8 hours of treatment with 1mg/ml CPAC (145).
Cranberry juice (CJ) at concentrations ranging from 50%, 30%, and 10%, was shown to reduce
bacteriophages T2 and T4 of E. coli strains C and B, and also simian rotavirus SA-11 after 30
min at 37oC, 23oC and 4oC from 9 log PFU/ml to undetectable levels by plaque assays (101).
However, concentrations lower than 10% did not show any significant reduction. Scanning
Electron Microscopy (SEM) studies showed that CJ treated phage T4 was unable to attach to
bacterial host cells as opposed to the control. Cranberry juice was also shown to inhibit
hemagglutination of rotavirus, where 20% CJ led to a complete hemagglutination inhibition. It is
proposed that CJ led to a change in glycoprotein moieties, which led to a failure in virus binding
the receptor cells (101). Cranberry juice and cranberry PAC (proanthocyanidins) were also found
to reduce human noroviral surrogates murine norovirus (MNV-1), feline calicivirus (FCV-F9),
MS2 bacteriophage, and phiX-174. Cranberry juice at pH 2.6 and 7, and CPAC at 0.15 mg/ml
and 0.3 mg/ml was shown to cause a complete reduction of FCV-F9 within 30mins. CJ at pH
2.6, 7.0 and CPAC at 0.15 mg/ml, 0.30 mg/ml PAC was found to cause log reductions of 1.90,
1.66, 2.24 and 2.94 log10 PFU/ml after 1h for MNV-1, respectively. For phi-X 174, reduction in
titers of 1.66, 1.24, 2.15 and 2.82 log10 PFU/ml was achieved after 1 h with CJ at pH 2.6, CJ at
pH 7.0, 0.15 mg/ml PAC and 0.30 mg/ml PAC (250).
Raspberries
Black raspberry (Rubus coreanus) is native to South Asian countries including China, Japan and
Korea. They are known for their anti-inflammatory, antibacterial, and antiviral properties. The
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fruit contains polyphenolic compounds including gallic acid and quercetin (251). When screened
for their antibacterial activity, black raspberry was shown to effective against multi drug resistant
Staphylococcus aureus (MRSA), Bacillus anthracis and Acinetobacter baumannii (252). MIC’s
of 250, 125 and 1000 µg/ml were reported for MRSA, B. anthracis and A. baumannii,
respectively. At 1% concentration, raspberry extract caused 80% inhibition on the growth of
Helicobacter pylori (150). Black raspberry juice (6%) was also shown to have antiviral effect on
the HNoV surrogate, MNV-1 causing reduction in plaque titers by 99% after 1 h (253). Cotreatment (simultaneous addition of treatment and virus to the host cells) was demonstrated to
exert maximal antiviral activity on bothFCV-F9 and MNV-1. The study suggested that the juice
exerted its antiviral effect by inhibiting viral attachment to host cells, though gallic acid and
quercitin did not have any significant effect (253).

Blackberries
Blackberry (Rubus fruticosus) fruits and plants have been used in herbal medicine for their
antimicrobial,

anticancer,

antidiabetic,

antidiarrheal,

and

antioxidant

properties(254). Blackberries contain phenolic compounds including tannins, gallic acid,
anthocyanins along with vitamin C, niacin, sugars, and some amounts of, citric acid and malic
acid (255). Blackberries were shown to reduce the oral pathogen Fusobacterium nucleatum by
1.5 log CFU with 1400 µg/ml of blackberry extract after 24h at 37oC (255). . Metabolic activity
of F. nucleatum was reported to reduce by 40% with 700 μg/mL of blackberry extract, while a
higher concentration of 1400μg/mL caused the metabolic activity to reduce by 84% (255).
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Extract from blackberry leaves were reported to have minimum bactericidal concentrations
(MBCs) against H. pylori strains G21 and 10K of 1200 µg/mL and 1500 µg/mL after 24h and
134 µg/mL and 270 µg/mL after 48 h, respectively(256). Blackberry extract at 56 μg/mL was
also shown to inhibit herpes simplex virus (HSV-1) replication in oral epithelial cells by
99%(255). Higher concentration of 280 μg/mL was shown to affect the virus adsorption and
entry into host cells.
Hibiscus extracts
Hibiscus sabdariffa commonly known as ‘roselle’ is an annual, tropical or subtropical shrub
species native to countries including Sudan, Mexico, India, and Thailand. It belongs to family
Malvaceae and calyces are often used in the preparation of beverages or for ornamental purposes
(Morton, 1987). Hibiscus calyces contains bioactive compounds including anthocyanins,
phenolic acids, organic acids, saponins, and alkaloids, gallic, chlorogenic, and protocatechuic
acid and these flavonoid compounds are responsible for the deep red color of the calyces (257,
258). The total phenolic content is around 77.2 mg GAE (gallic acid equivalents)/g for an
aqueous extract and 87.7 mg GAE/g for an ethanol extract (259). The calyces (aqueous extracts)
are considered GRAS (generally recognized as safe) and are approved for use as a food additive
by the U.S. by the Food and Drug Administration (21 CFR 172.510) in the flavoring of
beverages. Delphinidin-3-sambubioside and cyanidin-3-sambubioside are two anthocyanins
found in hibiscus extract that also contribute towards the antioxidant activity (260). Other
compounds present are gossypetin, quercetin, pectin, saponins, cardiac glycosides, and alkaloids
(261). These organic acids may also contribute to the antimicrobial activity, where the
undissociated form of the organic acid can enter the cell wall of bacteria, thereby stressing the
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cell by pH reduction cell and can lead to death (262). Organic acids including malic acid and
tartaric acid are also identified in the calyces resulting in the low pH of approximately 2-2.5
(263). Calyces of H. sabdariffa are known to possess a wide range of health benefits including
antioxidant, anti-diabetic, anticancer, cardio-protective and antimicrobial effects (264-266).
Aqueous extracts were also shown to be effective against methicillin-resistant S. aureus,
Klebsialla pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii with the MIC’s
of 32, 48, 56 and 48 mg/l respectively (267). Crude extracts of H. sabdariffa calyces were
reported to be effective against Propionibacterium acnes and Staphylococcus epidermidis, where
the MIC was reported to be 2.5 mg/ml and 0.625 mg/ml, respectively and MBC (minimum
bactericidal concentration) were reported to be to 5 mg/ml for both (268). Ethanol and aqueous
extracts of H. sabdariffa were also shown to have inhibitory effects against foodborne bacteria
such as E. coli O157:H7, Salmonella Typhimurium, Listeria monocytogenes, Bacillus cereus,
and S. aureus when added at levels of 5 or 10 mg added to 100 g ground beef or 100 ml apple
juice after 3 days of storage (269). Another study showed that the aqueous extracts at 100 % v/v
when used as a produce wash could reduce 4 log CFU/g of E. coli O157:H7 and Salmonella
enterica on lettuce after 24 h (270). In a recent study, H. sabdariffa extracts at concentrations of
0.5 to 2 mg/ml were also shown to inhibit biofilm formation in Candida albicans (271).
Protocatechuic acid (PCA) is an essential component of H. sabdariffa and has been demonstrated
to have several health beneficial properties (272). PCA has been shown to be the active
component responsible for the antimicrobial activity of H. sabdariffa (267). Ferulic acid, a
component of Hibiscus mutabilis has also been demonstrated to have antimicrobial properties
against common food borne bacteria including E. coli, S. aureus and L. monocytogenes (273).
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Ferulic acid was also demonstrated to possess antifilarial activity against Setaria cervi (274).
Conclusions
Overall, natural plant polyphenols appear to be promising alternates for use as preventive,
therapeutic or control options against the spread of foodborne illness. It is recognized that
effectiveness of antimicrobials can decrease in the presence complex food matrices where
components of foods such as lipids, proteins or other acidic or alkaline conditions may interfere
in the antiviral properties. Hence, it is necessary to determine their effects in model food
systems, environment, and in simulated gastrointestinal fluids to better understand their effects
and applications. To mimic the survival and behavior of viruses and antivirals in the gut, survival
studies using simulated gastric fluid (SGF) and simulated intestinal fluid (SIF) are necessary.
Survival studies in gastric environments have been reported previously with foodborne bacterial
pathogens such as E. coli, L. monocytogenes and V. vulnificus (275-277). Apple juice and milk
were chosen to study the effectiveness of tested treatments in this study. Apple juice is a food
product mainly consisting of carbohydrates (sugars including glucose, fructose, sucrose and
sorbitol), nonvolatile acids (malic, quinic, citric, shikimic, and fumaric), and phenolics
(chlorogenic acid and hydroxymethylfurfural) (278). In a study, cinnamon bark essential oil at
1,000 was shown to have bactericidal against L. monocytogenes with 3 log CFU/ml reduction in
skimmed milk and 1 log CFU/ml reduction in whole milk (279). The study suggested that
intrinsic parameters like fat and protein contents of the milk interact with the antimicrobial
substances that might reduce their activity. In addition to studying the effectiveness of these
antivirals in foods systems and the gut environment, it is also interesting to look into their
inactivation mechanisms. Several attempts have been made at understanding the mode of
antiviral action against these noroviral surrogates using various techniques like electron
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microscopy studies, binding studies, molecular assays and in vitro cell culture assays (144, 197,
253). Viruses are known to cross the host epithelial barrier through attachment to carbohydrate
moieties of host cell glycoproteins, glycolipids such as sialic acid, and proteoglycans (280).
Human noroviruses in addition to binding to histo-blood group antigens are also known to bind
to porcine gastric mucin (PGM) (281). PGM has been used widely in studies to discriminate
between infectious and non-infectious norovirus particles (282).
The objectives of this research were (1) to evaluate the antiviral properties of blueberry
proanthocyanidins (B-PAC) and commercial blueberry juice (BJ) against human norovirus
surrogates, namely feline calicivirus (FCV-F9) and murine norovirus (MNV-1); hepatitis A virus
and Aichi virus; (2) to determine the antiviral activity of BJ and B-PAC against these test viruses
in model food systems and under simulated gastric conditions and (3) to understand the
mechanism of action of B-PAC and BJ against the tested viruses.
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Appendix A
Table 1.1 General properties of common foodborne viruses
Family
Genus
Genome
Particle size
(nm)
Envelope
Route
of
transmission
Incubation
period

Symptoms

Vaccine

HNoV
Caliciviridae;
Norovirus
(+) ssRNA,
7.5 kb

HAV
Picornaviridae
Hepatovirus
(+) ssRNA,
7.5 kb

Aichi virus
Picornaviridae;
Kobuvirus
(+) ssRNA,
8.2 kb

Rotavirus
Reoviridae;
Enterovirus
dsRNA,
7.5 kb

HEV
Hepevirus;
Hepeviridae
(+) ssRNA,
7.3 kb

27-38

27-32

27-30

30

27-34

No

No

No

No

No

Fecal oral

Fecal oral

Fecal oral

Fecal oral

Fecal oral

24-48 h

4 weeks

24-48 h

2-4 days

40 days

Malaise, dark
urine, nausea,
vomiting,
jaundice

Diarrhea,
abdominal pain,
nausea, vomiting

Vomiting,
diarrhea,
dehydration,
fever

Available

Not available

Available

Diarrhea,
nausea,
vomiting,
abdominal
pain
Not available

*HNoV: human norovirus; HAV: hepatitis A virus; HEV: hepatitis E virus
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Jaundice,
anorexia,
Acute liver
failure
Available

Table 1.2 Human norovirus outbreaks
Year
2014

Sample type
Clinical

Contamination source/Location
Cruise ship
Unknown source (tourists), Yellow
stone national park
Imported frozen raspberries
Pasta, raw vegetables/ French military
unit

Detection method
Not known

2013

Not known

2012

Food

2011

Stool sample

2009

Clinical, food,
environmental

Salad/German military base

RT PCR

2009

Stool

Water resort

2009
2008

Clinical
Water

Cruise ship
Municipal drinking water/Sweden

2008

Clinical

University dining hall

2003

Food and
clinical

Oysters

69

Epidemiology
Epidemiology
RT PCR

RT-qPCR,
Epidemiology
RT-qPCR
Epidemiology
Epidemiology; RT
PCR
Epidemiology; RT
PCR

Reference
(8)

CDC, 2013
(283)
(284)
(285)
(286)
(287)
(288)
(289)
(290)

Table 1.3 Hepatitis A virus outbreaks
Year

Sample type

2013

Food

2011
2011
2009

Food
Serum
Serum

Contamination
source/Location
Frozen berries in
smoothies/ Nordic
countries
Sundried tomatoes
Sushi bar, Japan
Sun dried tomatoes

2009

Serum

Well water

2008

Serum/ stool

2004

Clinical

2003

Serum

Thai navy base
Orange Juice/
Egyptian restaurant
Green onions

Detection method

Reference

Epidemiology

(291)

Epidemiology
RT PCR
RT PCR
Epidemiology, detection of antiIgM
Detection of anti-IgM, RT-PCR

(53)
(292)
(52)
(293)

RT PCR
Epidemiology, RT-PCR
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(294)
(295)
(54)

Table 1.4 Rotavirus and Hepatitis E virus outbreaks
Virus Type

Rotavirus

Hepatitis
E virus

Contamination
source/Location
French Reunion
island
Retirement
communities
Intensive care
unit/Brazil
Pediatric
hospital/Mexico

Year

Sample type

2012

Clinical

2011

Clinical

2011

Clinical

2007

Clinical

1997

Stool, Serum

Pediatric unit/Toys

Epidemiology, EIA

2011

Serum

Italy

RT PCR, Detection
of IgG and IgM by
immunoassay

2011

Food

Shellfish/England

RT PCR

2007

Blood

Uganda

RT PCR

71

Detection method
RT PCR
EIA, RT PCR
RT PCR
ELISA

Reference
(296)
(297)
(298)
(299)
(300)
(301)

(302)
(303)

Table 1.5 Effect of grape seed extract (GSE) and its components against viruses
Type of
bioactive

GSE

Concentration

1 mg/ml

0.2 mg/ml
40 μg/mL

Resveratrol

20 uM

10μM

Virus

Reduction

Reference

FCV-F9

4.61 log PFU/ml

MNV-1

1.73 log PFU/ml

HAV

3.2 log PFU/ml

MNV-1

3 log PFU/ml

(144)

Influenza

Complete

(201)

virus

inhibition

Polyomavirus

Complete
inhibition

Human

20-30%

immunodeficiency

reduction in

virus – 1

replication

*FCV-F9: feline calicivirus; MNV-1: murine norovirus; HAV: hepatitis A virus

72

(197)

(202)

(304)

Table 1.6 Antiviral activity of blueberry polyphenols
Type of bioactive

Concentration

Virus

Effect

Blueberry

5.47 µg/ml

Hepatitis C virus

Inhibition of

proanthocyanidin

Reference
(156)

subgenome
expression

Tannins

0.03-0.1 µg/ml

Herpes

simplex Inhibition of

virus

(157)

adsorption
to its host

Blueberry juice

0

4 C after 1 day

FCV-F9

Reduction to
undetectable
levels

*FCV-F9: feline calicivirus

73

(2)

Table 1.7 Antiviral properties of additional fruit extracts
Type of bioactive
Cranberry juice

Concentration
30 min

Virus

Effect

FCV-F9

Reduction to undetectable

Reference
(250)

levels
Cranberry juice

30%

Simian

Reduction to undetectable

(101)

rotavirus SA- levels
11
CPAC

0.15-0.3mg/ml

FCV-F9

Reduction to undetectable

(250)

levels

Black raspberry
juice
Blackberries
Pomegranate
polyphenols

6%

MNV-1

99% reduction

(253)

56 μg/mL
800 μg/ml
5 min at room
temperature

99% reduction
3 log PFU/ml reduction

(255)
(239)

Pomegranate juice

Room
temperature
1h

HSV-1
Human
influenza
viruses
(H1N1,
H3N2, and
H5N1)
FCV-F9

2.56 log PFU/ml

(241)

MNV-1

1.32 log PFU/ml

MS2

0.32 log PFU/ml

*FCV-F9: feline calicivirus; MNV-1: murine norovirus; HAV: hepatitis A virus
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Figure 1.1 Representative structures of ﬂavan-3-ol monomers and their dimers (B-type PACs).
When R1= OH and R2= H, the monomer is (-)-epicatechin. When R1= H and R2= OH, then the
monomer is (+)-catechin. (Adapted from Hammerstone et al., 2000).

Figure 1.2. A-type and B-type PACs (Adapted from Blumberg et al., 2013)
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Blueberry and blueberry extracts are known for their health benefits and antimicrobial properties.
Natural therapeutic or preventive options to decrease the incidences of foodborne viral illnesses
are becoming popular and being researched. This study aimed to determine the antiviral effects
of blueberry juice (BJ) and blueberry proanthocyanidins (B-PAC) against the infectivity of
hepatitis A virus (HAV), Aichi virus (AiV) and human norovirus surrogates (feline calicivirus
(FCV-F9) and murine norovirus (MNV-1)) at 37ºC over 24-h using standard plaque assays.
Viruses at ~5 log PFU/ml were mixed with equal volumes of BJ (pH 2.8), neutralized BJ (pH
7.0), B-PAC (1, 2, 4, and 10 mg/ml), malic acid (pH 3.0), or phosphate buffered saline (pH 7.2)
and incubated over 24-h at 37oC. Each experiment was carried out in duplicate and replicated
thrice. FCV-F9 titers were found to be reduced to undetectable levels with 1 and 2 mg/ml B-PAC
after 5 min, after 1 h with 0.5 mg/ml B-PAC, and with BJ after 3-h. MNV-1 titers were reduced
to undetectable levels after 3-h with 1, 2, and 5 mg/ml B-PAC and after 6-h with BJ. HAV titers
were reduced to undetectable levels after 30 min with 2 and 5 mg/ml B-PAC, after 3-h with 1
mg/ml B-PAC, and by ~2 log PFU/ml with BJ after 24-h. B-PAC at 5 mg/ml reduced AiV titers
to undetectable levels after 3 h, while BJ caused reductions to undetectable levels after 24 h. BPAC shows potential to control enteric viruses in a dose and time-dependent manner, although
further in vitro studies in model food systems and in vivo studies using animal models are
warranted.
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Introduction
Foodborne pathogens in the United States lead to an estimated 9.4 million illnesses, 55,961
hospitalizations, and 1,351 deaths of which foodborne viruses such as human norovirus alone are
responsible for 5.5 million illnesses (58%) per year (1). Recent reports indicate that this number
has risen to 21 million illnesses per year (2). Human norovirus and hepatitis A virus have been
linked to several foodborne and waterborne outbreaks in the US as well as worldwide (3). Aichi
virus is an emerging pathogen is transmitted via the fecal-oral route and shed in the feces and
hence seafood like shellfish from sewage-contaminated water can be a source of contamination
(4, 5). AiV-related gastrointestinal cases have been reported all over the world including in
Asian, African, European and South American countries (6-11). These foodborne viruses are
now recognized worldwide as public health concerns and therefore effective natural alternatives
to control their spread are being researched. This is important for the treatment or potential
alleviation of illness symptoms and prevention of disease in the current absence of available
vaccines for human noroviruses. Recently, the antiviral effects of grape seed extract (GSE)
against human norovirus surrogates, FCV-F9 and MNV-1, and hepatitis A virus (HAV) at 37ºC
for 2 h were reported (12). Cranberry juice and its proanthocyanidins were also reported to cause
reduction of human norovirus surrogates (13).
Blueberries also contain structurally related polyphenols, including anthocyanins,
flavonoids, and proanthocyanidins (PAC), sometimes referred to as condensed tannins (14).
Blueberries and its polyphenols have been evaluated for their potential health benefits including
their anticarcinogenic, neuroprotective, cardioprotective, antibacterial, and antiviral properties
(15-19). Blueberry extracts at a concentration of 0.25% are known to have antimicrobial activity
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and are reported to cause 50.5% inhibition of Helicobacter pylori, the bacterium associated with
ulcers (20). Water and ethanol extracts of blueberries at 24 ppm were reported to cause a 5.90
log CFU/ml reduction of Listeria monocytogenes after 24 h at 37ºC in vitro (21). Recently,
monomeric phenolics acids (0.4g/L gallic acid) from blueberries were shown to reduce
Escherichia coli O157:H7 by 5 log CFU/ml along with cell-membrane damage after 24 h at37ºC
in vitro (22). Additionally, using the HCV replicon cell system, the methanol extract fraction of
blueberry leaves (0.112–2200 μg/ml) was shown to inhibit hepatitis C (HCV) virus subgenomic
expression after 72h at 37ºC (23). Hydrolysable and galloylated tannin (0.03–0.1 μg/ml) was
reported to inhibit the adsorption of herpes simplex virus to its hosts, African green monkey
kidney cells and human adenocarcinoma cells at 37oC (24). Human norovirus surrogates such as
feline calicivirus (FCV-F9) and murine norovirus (MNV-1) have been studied for survival in
commercial blueberry juice (BJ) at 4ºC, where FCV-F9 was undetectable after 24 h from initial 5
log PFU/ml, whereas MNV-1 showed minimal reduction after 21 days at 4ºC (25).
Blueberries and blueberry phenols could potentially be used as part of a diet to prevent or
treat human norovirus related gastroenteritis. Therefore, the objective of this study was to
determine the effect of blueberry juice (BJ) and blueberry proanthocyanidins (B-PAC) on the
infectivity of hepatitis A virus (HAV), Aichi virus (AiV) and human norovirus surrogates (FCVF9 and MNV-1) at 37ºC over a period of up to 24 h using standardized plaque assays.
Materials and Methods
Viruses and cell lines
Feline calicivirus (FCV-F9) and host Crandell Reese Feline Kidney (CRFK) cells were
purchased from ATCC (ATCC identifying number VR-2057; Manassas, VA). Murine norovirus
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(MNV-1) was kindly gifted by Dr. Skip Virgin (Washington Univ., St. Louis, MO) and RAW
264.7 cells were obtained from the University of Tennessee at Knoxville.Hepatitis A virus
(HAV; strain HM175) and fetal rhesus monkey kidney (FRhK4) cells were provided by our
collaborator, Dr. Kalmia Kniel (University of Delaware). Aichi virus (AiV) was kindly provided
by Dr. David Kingsley (USDA ARS, Delaware) and propagated using Vero host cells. Host cell
lines were maintained using Dulbecco’s Modified Eagle’s Medium/Ham’s F-12 (DMEM-F12;
HyClone Laboratories, Logan, UT) containing 2 or 10% heat-inactivated fetal bovine serum
(FBS, HyClone Laboratories) and 1x Anti-Anti (Antibiotic-Antimycotic, Invitrogen, Grand
Island, NY) at 37ºC in an atmosphere containing 5% CO2.
Propagation of viruses
To prepare stocks of FCV-F9, MNV-1, AiV and HAV, respective host cell lines at 90%
confluency were inoculated with each virus and incubated for 2, 6, 3 and 8 days, respectively
under 5% CO2 at 37ºC. The viruses were harvested by 1 to 3 freeze thaw cycles followed by
centrifugation at 5,000 xg for 10 min. The supernatant was filtered through a 0.2-m filter,
aliquoted, stored at -80ºC until further use and titers of the recovered viral stocks were
determined using standard reported plaque assays (13, 26).
Propagation of viruses
To prepare stocks of FCV-F9, MNV-1, AiV and HAV respective host cell lines at 90%
confluency were inoculated with each virus and incubated for 2, 6, 3 and 8 days, respectively
under 5% CO2 at 37ºC. The viruses were harvested by 1 to 3 freeze thaw cycles followed by
centrifugation at 5,000 xg for 10 min. The supernatant was filtered through a 0.2-m filter,
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aliquoted, stored at -80ºC until further use and titers of the recovered viral stocks were
determined using standard reported plaque assays (13, 26).
Isolation of PAC from blueberries
Proanthocyanidins were isolated from frozen highbush blueberry fruit (Vaccinium corymbosum
L.) using solid-phase chromatography according to a well-established method for
proanthocyanidin isolation (27). Briefly, blueberry fruit was homogenized with 70% aqueous
acetone, filtered and the pulp discarded. The collected extract was concentrated under reduced
pressure to remove acetone. The blueberry extract was suspended in water, applied to a
preconditioned C-18 solid phase chromatography column and washed with water to remove
sugars, followed by acidified aqueous methanol to remove acids. The fats and waxes retained on
the C-18 sorbent were discarded. The polyphenolic fraction containing anthocyanins, flavonol
glycosides and proanthocyanidins (confirmed using reverse phase HPLC with diode array
detection) was eluted with 100% methanol and dried under reduced pressure. This fraction was
suspended in 50% EtOH, applied to a pre-conditioned Sephadex LH-20 column which was
washed with 50% EtOH to remove low molecular weight anthocyanins and flavonol glycosides.
Proanthocyanidins adsorbed to the LH-20 were eluted from the column with 70% aqueous
acetone, and monitored using diode array detection at 280 nm. The absence of absorption at 360
nm and 450 nm confirmed that anthocyanins and flavonol glycosides were removed. Acetone
was removed under reduced pressure and the resulting purified proanthocyanidin extract freezedried. Electrospray mass spectrometry,

13

C NMR, matrix-assisted laser desorption/ionization

time-of-flight mass spectrometry and acid catalyzed degradation with phloroglucinol have all
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been utilized to confirm the purity of proanthocyanidins present in the extract obtained using this
method (27).
Effect of BJ and B-PAC on host cells lines
Cytopathic effects of B-PAC, BJ (pH 2.8) and NBJ (neutralized blueberry juice; pH 7.0)
treatments on the host cell lines were also determined. The maximum concentration of B-PAC
used in the viral treatment and assays was 5 mg/ml. However, the host cell lines were exposed to
only a 20-fold dilution of the treatment after neutralization/stopping of the treatment. Thus, each
individual host cell lines on confluent 6-well plates were exposed to B-PAC at 0.5 mg/ml and BJ
and NBJ for 2 h at 37oC and observed under optical microscope (Fisher Scientific; 120 VAC) to
determine visible cytopathic effects or changes.
Antiviral effect of BJ and B-PAC
Commercial blueberry juice (cocktail with grape and apple juice; preservatives listed include
malic acid and sodium citrate) was purchased from local grocery stores and B-PAC was
fractionated by Dr. Amy Howell (Marucci Center for Blueberry and Cranberry Research,
Rutgers University, Chatsworth, NJ) and kindly gifted for this work. B-PAC was dissolved in
10% ethanol and filter-sterilized through 0.2-micron filters to obtain a stock of 10 mg/ml. Equal
volumes of each virus at a titer of ~5 log PFU/ml was individually mixed with BJ (pH 2.8), BPAC (1, 2, 4, and 10 mg/ml), malic acid (pH 3.0), neutralized BJ (pH 7 using 4 M sodium
hydroxide, NaOH), 10% ethanol or phosphate buffered saline (PBS; 7.2 as control) and
incubated at 37ºC for 5 (0.08 h), 15 (0.25h), 30 (0.5h), 60 (1h), 120 (2 h), 180 (3 h), 360 min (6
h) or 24h. Treatments were stopped using initial serial dilutions of the treated virus with cell83

culture media containing 10% heat-inactivated FBS, followed by dilutions in cell-culture media
containing 2% FBS. The infectivity of viruses was evaluated using standard plaque assays as
described before (13). Each experiment was replicated thrice and assayed in duplicate.
Statistical analysis
Statistical analysis was carried out using ANOVA with SAS software (version 9.3, SAS Institute,
Cary, NC, USA) and Tukey’s test with data obtained from the three replications for each
individual virus as described in previous studies (12, 28).
Results
Effect of B-PAC and BJ on host cells lines
B-PAC at a concentration of 0.5 mg/ml was not found to be cytotoxic to the tested host cell lines.
Undiluted BJ when added directly to the host cells had some minor effects after 2h. However,
neutralized BJ (NBJ) did not show any morphological visual changes in the host cells and was
used further in the time of addition experiments. In the experiment involving treatment of viruses
with B-PAC, the cells are exposed to a maximum of 20-fold diluted B-PAC and hence the host
cells do not show cytopathic effects.
Reduction of viral titers by B-PAC and BJ
All four tested viruses were found to be susceptible to the B-PAC treatment carried out at 37oC.
FCV-F9 from initial titers of ~5 log PFU/ml were reduced to undetectable levels (to <102PFU/ml
per detection limit of the assay) after 5 min with 1, 2, and 5 mg/ml B-PAC, and to undetectable
levels (> 3 log PFU/ml reduction) after 60 min with 0.5 mg/ml B-PAC. After 5 min, lower
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concentration of 0.5 mg/ml B-PAC reduced FCV-F9 titers by only 1.33±0.03 log PFU/ml and
after 30 min by 2.19±0.22 log PFU/ml (Table 2.1). MNV-1 was less sensitive to B-PAC
treatments compared to FCV-F9, where MNV-1 at initial titers of~5 log PFU/ml were reduced to
undetectable levels only after 3 h with 1, 2, and 5 mg/ml of B-PAC. Lower concentration of 0.5
mg/ml B-PAC caused MNV-1 reductions of 1.47±0.05 log PFU/ml after 3 h and caused slightly
higher reductions of 1.83±0.10 log PFU/ml after 6 h. (Table 2.2). HAV titers were reduced to
undetectable levels after 30 min with 2 and 5 mg/ml B-PAC, whereas 1 mg/ml B-PAC reduced
HAV titers by 1.71±0.21 log PFU/ml after 30 min and to undetectable levels only after 3 h
(Table 2.3). Lower concentration of 0.5 mg/ml B-PAC caused mere reductions of 0.55±0.04,
0.79±0.06 and 0.69±0.04 log PFU/ml in HAV titers after 1, 3 and 6 h at 37oC. B-PAC (1 mg/ml)
at 37oC was shown to be effective in reducing AiV titers by 0.48±0.01, 1.50±0.02, 1.84±0.25,
1.45±0.35 and 2.13±0.06 PFU/ml after 0.5, 1, 3, 6 and 24 h, respectively. Increased
concentration caused higher titer reduction where 2 mg/ml B-PAC caused reductions of
0.93±0.10, 1.63±0.22, and 1.82±0.07 log PFU/ml after 0.5, 1, and 3 h respectively and to
undetectable levels after 6 and 24 h. The highest tested concentration of B-PAC at 5 mg/ml was
found to be the most effective that caused reductions of 1.39 ± 0.04 and 1.76 ± 0.54 log PFU/ml
after 0.5 and 1 h, respectively, and to undetectable levels after 3 h (Table 2.4).
Commercial BJ did not have a prominent effect on the viral titers after shorter contact times.
Among the three tested viruses, FCV-F9 was the most sensitive, where BJ reduced FCV-F9 titers
to undetectable levels after 3 h (Table 2.5). However, BJ did not have a significant effect on
MNV-1 and HAV after 3 h. MNV-1 titers were reduced to undetectable levels only after 24 h
with BJ while HAV was reduced by 1.86±0.05 log PFU/ml after 24 h with BJ (Table 2.6 and
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2.7). Both, malic acid (pH 3.0, control) and neutralized BJ (pH 7.0) did not have any significant
effect in reducing the titers of all FCV-F9, MNV-1 and HAV, compared to non-neutralized BJ
(pH 2.8) that showed ~2-3 log PFU/ml reduction after 24 h. Thus, the reduction cannot be
attributed solely to pH effects, indicating that BJ bioactives contributed to the reduction.
Treatment of AiV at ~5 log PFU/ml with BJ at 37oC resulted in titer reductions of 0.17±0.06,
1.27±0.01 and 1.73±0.23, log PFU/ml after 1, 3 and 6 h, and to undetectable levels after 24 h.
Neutralized BJ (pH 7.0) showed 0.07±0.11, 0.0±0.0, 0.06±0.07 and 0.23±0.11 log PFU/ml after
1, 3, 6 and 24 h. Malic acid (pH 3.0, acid control) was shown to have minimal effects on virus
infectivity over time though to a much lesser extent than BJ within 6 h, causing titer reductions
of 0.08±0.0, 0.25±0.06 and 0.84±0.23 log PFU/ml after 1, 3 and 6 h and to undetectable levels
after 24 h, indicating that low pH also contributes to the antiviral effect of BJ on AiV over
extended time (Table 2.8).
Discussion
B-PAC and BJ were found to be effective in reducing the titers of all the three tested viruses. BPAC showed dose and time-dependence effects against the four tested viruses where higher
concentration and longer time had the greatest antiviral effects especially for MNV-1 and HAV.
Between the two tested human norovirus surrogates, FCV-F9 was found to be the more sensitive
surrogate to treatments than MNV-1. This is not surprising as similar patterns are reported when
comparing FCV-F9 and MNV-1 using chemical treatments and plant-derived extracts such as
trisodium phosphate (TSP) and GSE (12, 29). Previous studies have also shown that MNV-1 is
the sturdier of the surrogates when exposed to extreme heat and pH (30). HAV was found to be
moderately sensitive to B-PAC treatment where complete reduction was achieved with 2 and
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5mg/ml B-PAC after 30 min. HAV is known to be highly stable in the environment and can
retain infectivity for long periods of time, and can survive in mineral water stored at room
temperature up to 300 days (31). It is also resistant to extreme acidic pH, where it was shown to
survive in acidic marinade at pH 3.75 over 4 weeks and even at pH 1.0 even after 5 h (32, 33).
Thus, the antiviral effect of B-PAC against HAV is quite noteworthy.
Bioactive compounds such as gallic acid, epicatechin, tannins, and proanthocyanidins
found in berry fruits are known to be effective antimicrobial agents (34-36). Polyphenols from
fruits such as pomegranate, cranberry, grapes (seed), and other plant extracts have been shown to
possess antiviral properties including against human norovirus surrogates (13, 37, 38). FCV-F9
was found to be undetectable after 1 day in BJ as well as in orange and
pomegranate juice blend at 4°C (25, 39). MNV-1 was reported to be completely reduced after 7
days in the orange and pomegranate juice blend, however only 1 log PFU/ml reduction of MNV1 was observed in BJ at 4ºC after 14 days (25, 39). Black raspberry juice at 6% was found to
reduce MNV-1 plaque formation by 99% after 1 h at 37ºC (38). However in the current study, BJ
treatment needed longer contact time to achieve similar reduction, which could be attributed to
the fact that black raspberry juice was freshly made by hand, and might have higher
concentration of polyphenols, whereas commercially available BJ was used in our study. Grape
seed extract (GSE), cranberry proanthocyanidins (CPAC) and pomegranate polyphenols (PP)
have been reported for their antiviral properties against FCV-F9 and MNV-1 (12, 13, 37).FCVF9 and MNV-1 were reduced to undetectable levels and by 2.95 log PFU/ml, respectively with
0.6 mg/ml CPAC after 1 h at RT (40).GSE at 0.5 and 1 mg/ml reducedFCV-F9 titers to
undetectable levels within 15 min at 37oC and RT, and MNV-1 titers were reduced by ~1 log
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PFU/ml after 1 h at 37oC and RT (12). FCV-F9 and MNV-1 were also sensitive to PP treatments
at RT, where PP at 2 mg/ml decreased FCV-F9 titers to undetectable levels after 30 min and
MNV-1 titers were reduced by 0.9 log PFU/ml after 60 min (37). In this study, B-PAC at 2
mg/ml reduced FCV-F9 titer to undetectable levels within 5 min and MNV-1 by 1.65 log
PFU/ml after 60 min at 37oC.When comparing these polyphenol extracts for their antiviral
activity against FCV-F9 and MNV-1, their effect follows the order of CPAC>GSE>B-PAC>PP.
In comparison to human norovirus surrogates, fewer studies are reported in literature on
the antiviral effects of natural extracts against HAV. In a previous study, GSE at 1mg/ml was
shown to reduce HAV titers from initial 5 log PFU/ml by 2.89 log PFU/ml after 2h at 37oC (12).
HAV titers at initial 5.74 log PFU/ml were also shown to be decreased by 0.66 log PFU/ml when
treated with 10 μg/mL Korean red ginseng, and decreased by 0.37 log PFU/ml when treated with
10 μg/mL purified ginsenoside extract after 24 h at 37oC (41). B-PAC treatment, although at a
higher concentration, was found to be effective in reducing HAV titers where 2mg/ml B-PAC
caused reduction to undetectable levels within 30 min at 37oC.
A few other studies have reported AiV to be resistant to inactivation treatments. Essential
oil extracts from Origanu macutidens were shown to be ineffective in inhibiting AiV replication
in vivo (42). AiV remained fully infectious after a 5-min treatment at 600 MPa in MEM
(minimum essential medium) supplemented with 2 and 10% FBS, respectively (43). AiV
reductions on lettuce, green onions, and strawberries at 240 mW s/cm2 were 4.59, 2.49, and 1.87
log TCID50 /ml, respectively (26). This suggests that AiV is quite resilient to physical
inactivation treatments. In this study B-PAC treatments were more effective in comparison to
most of the reported disinfectant treatments. AiV reductions of 1.39 and 1.76 log PFU/ml were
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seen after 0.5 and 1 h with 5 mg/ml B-PAC and reduction to undetectable levels was obtained
after 3 h with 5mg/ml B-PAC.
Neutralized BJ did not have any significant effect in reducing the viral titers. As PACs
are known to be stable under acidic conditions, increasing the pH can change the structure of
PAC, thereby potentially changing its bioactivity. Moreover, the malic acid (pH 3.0) pH control
by itself alone also did not significantly contribute to the titer reduction. It could be speculated
that both the bioactive components of BJ and the acidic pH together contributed towards the
antiviral activity. Bioactive components of BJ were not individually analysed for antiviral
activity in this study.
It is well recognized that effectiveness of antimicrobials can decrease in the presence
complex food matrices where components of foods such as lipids, proteins or other acidic or
alkaline conditions may interfere with the antiviral properties. Hence, along with studying the
effect of these blueberry polyphenols on the viral infectivity in vitro, it is also crucial to further
investigate their effectiveness in presence of food matrices and under simulated gastric
conditions for use as potential antiviral therapeutics. Some studies have been conducted with
plant extracts (hibiscus) in milk and apple juice against E. coli and Staphylococcus aureus where
antimicrobial activity was shown to reduce in foods with higher lipid and protein load (44). A
similar study was carried out using black tea and tea in milk against oral pathogen Streptococcus
mutans, where reduced antimicrobial activity of tea made in milk was reported (45). This
decrease in activity was attributed to complex formation of milk proteins and tea polyphenols
and subsequent decrease in the bioavailability of polyphenols (45). Therefore, future studies are
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aimed to determine the antiviral effects of B-PAC in food systems such as milk (high in lipids)
and apple juice, and also simulated gastric conditions.
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Appendix B
Table 2.1 Effect of 0.5 to 5 mg/ml blueberry proanthocyanidins (B-PAC) on FCV-F9 at ~ 5 log PFU/ml at 37oC over 2 h.
Time
PBS
(Min)
5
4.87 ± 0.07A
30
4.83 ± 0.05A
60
5.03 ± 0.06A
120 5.03± 0.06A
A, B, C, D

Recovered titer (Log PFU/ml)
Ethanol
B-PAC
B-PAC
B-PAC
B-PAC
(10%)
(0.5 mg/ml) (1 mg/ml) (2 mg/ml) (5 mg/ml)
A
4.76 ± 0.05 3.54 ± 0.10B
0D
0D
0D
4.77 ± 0.06A 2.64 ± 0.27C
0D
0D
0D
4.73 ± 0.06A
0D
0D
0D
0D
4.99± 0.06A
0D
0D
0D
0D

Different letters denote significant differences when compared between each column (p<0.05). Detection limit for the assay is 2 log PFU/ml.

Table 2.2 Effect of 0.5 to 5 mg/ml blueberry proanthocyanidins (B-PAC) on MNV-1 at ~ 5 log PFU/ml at 37oC over 6 h.
Time
(Min)
30
60
120
180
360
A, B, C, D

PBS
4.89 ± 0.08A
4.84 ± 0.10A
4.76 ± 0.01A
4.75 ± 0.07A
4.63 ± 0.17A

Recovered titer (Log PFU/ml)
Ethanol
B-PAC
B-PAC
B-PAC
B-PAC
(10%)
(0.5 mg/ml)
(1 mg/ml)
(2 mg/ml)
(5 mg/ml)
A
AB
BC
BC
4.56 ± 0.08 3.80 ±0.06
3.71±0.05
3.43±0.09
3.28 ± 0.22BC
4.82 ± 0.08A 3.67 ± 0.13B 3.49±0.08BC 3.19 ±0.19C 2.78±0.28C
4.56 ± 0.08A 3.70 ± 0.13B 3.46±0.06BC 3.17 ±0.12C 2.76±0.09C
4.75 ± 0.07A 3.28 ± 0.12B
0D
0D
0D
4.61 ± 0.07A 2.80 ± 0.07C
0D
0D
0D

Different letters denote significant differences when compared between each column (p<0.05). Detection limit for the assay is 2 log PFU/ml.
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Table 2.3 Effect of 0.5 to 5 mg/ml blueberry proanthocyanidins (B-PAC) on HAV at ~ 5 log PFU/ml at 37oC over 3 h.
Time
(Min)
15
30
60
180
360
A, B, C

PBS
4.81 ± 0.05A
4.78 ± 0.03A
4.83 ± 0.07A
4.85 ± 0.12A
4.81 ± 0.13A

Ethanol
(10%)
4.80 ± 0.04A
4.75 ± 0.03A
4.71 ± 0.13A
4.77 ± 0.16A
4.61 ± 0.16A

Recovered titer (Log PFU/ml)
B-PAC
B-PAC
(1 mg/ml)
(2 mg/ml)
B
3.27 ± 0.08
2.79 ± 0.16C
3.07 ± 0.24C
0D
2.58 ± 0.14C
0D
0D
0D
0D
0D

B-PAC
(0.5 mg/ml)
NP**
NP**
4.28 ± 0.11A
4.06 ± 0.18AB
4.12 ± 0.09AB

B-PAC
(5 mg/ml)
2.35 ±0.12C
0D
0D
0D
0D

Different letters denote significant differences when compared between each column (p<0.05). Detection limit for the assay is 2 log PFU/ml.

**NP= not performed
Table 2.4 Reduction of Aichi Virus (AiV) by blueberry proanthocyanidins (B-PAC) at 37oC over 24 h.
Recovered titer (Log PFU/ml)
Time
(Hour)

A, B, C

PBSa

Ethanol
(10%)

0.5

4.75 ± 0.07A

4.57 ± 0.14A

1

4.62 ± 0.04A

3

B-PAC
(1 mg/ml)

B-PAC
(2 mg/ml)

B-PAC
(5 mg/ml)

4.27 ± 0.08AB

3.82±0.17B

3.36 ± 0.11B

4.53 ±0.06A

3.12±0.10C

2.99±0.26C

2.86±0.58C

4.53 ± 0.05A

4.58 ± 0.08A

2.69±0.29C

2.71±0.12C

0D

6

4.45 ± 0.11A

4.59 ± 0.07A

3.00±0.36C

0D

0D

24

4.43 ± 0.06A

4.52 ± 0.07A

2.30±0.00C

0D

0D

Different letters denote significant differences when compared between each column (p<0.05). Detection limit for the assay is 2 log PFU/ml
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Table 2.5 Effect of blueberry juice (BJ) on FCV-F9 at ~ 5 log PFU/ml at 37oC over 6h.

Time
(Min)

PBS

30
60
120
180
360

4.83 ± 0.05A
5.17 ± 0.10A
5.17 ± 0.10A
4.85 ± 0.05A
4.99 ± 0.07A

A, B, C, D, E

Recovered titer (Log PFU/ml)
Malic acid
Neutralized
Blueberry Juice
(pH 3.0)
Blueberry Juice
(pH 2.8)
(pH 7.0)
A
B
4.85 ± 0.04
4.39 ± 0.08
4.87 ± 0.03A
4.85 ± 0.04A
3.58 ± 0.09C
4.84 ± 0.08A
4.80 ± 0.03A
2.76 ± 0.30D
4.74 ± 0.02A
4.39 ± 0.12B
0E
4.77 ± 0.04AB
4.39 ± 0.12B
0E
4.76 ± 0.03AB

Different letters denote significant differences when compared between each column (p<0.05). Detection limit for the assay is 2 log PFU/ml.

Table 2.6 Effect of blueberry juice (BJ) on MNV-1 at ~ 5 log PFU/ml at 37oC over 6 h.

Time
(Hour)

PBS

1
3
6
24

4.57 ± 0.07A
4.75 ± 0.07A
4.50 ± 0.07A
4.04 ± 0.19 C

A, B, C

Recovered titer (Log PFU/ml)
Neutralized
Malic acid
Blueberry Juice
Blueberry Juice
(pH 3.0)
(pH 2.8)
(pH 7.0)
A
A
4.79 ± 0.04
4.33 ± 0.05
4.33 ± 0.05A
4.78 ± 0.02A
4.26 ± 0.12B
4.26 ± 0.12A
4.45 ± 0.05A
4.02 ± 0.13 AB
4.02 ± 0.13AB
4.12 ± 0.09 AB
0D
3.88 ± 0.18C

Different letters denote significant differences when compared between each column (p<0.05). Detection limit for the assay is 2 log PFU/ml.

96

Table 2.7 Effect of blueberry juice (BJ) on HAV at ~ 5 log PFU/ml at 37oC over 24 h.

Time
(Hour)

PBS

1
2
3
6
24

4.78 ± 0.04A
4.77 ± 0.02A
4.90 ± 0.05A
4.80 ± 0.05A
4.63 ± 0.07A

A, B, C, D

Recovered titer (Log PFU/ml)
Neutralized
Malic acid Blueberry Juice
Blueberry Juice
(pH 3.0)
(pH 2.8)
(pH 7.0)
A
A
4.76 ± 0.05
3.63 ± 0.07
4.73 ± 0.05A
A
B
4.77 ± 0.07
3.85 ± 0.05
4.72 ± 0.02A
4.76 ± 0.05A 3.63 ± 0.32BC
4.79 ± 0.03A
4.47 ± 0.12A
3.45 ± 0.05C
4.52 ± 0.22A
4.32 ± 0.04A
2.77 ± 0.12D
4.52 ± 0.22A

Different letters denote significant differences when compared between each column (p<0.05). Detection limit for the assay is 2 log PFU/ml.

Table 2.8 Effect of blueberry juice (BJ) on Aichi virus (AiV) at ~ 5 log PFU/ml at 37oC over 24 h.
Recovered titer (Log PFU/ml)

A, B, C, D

Time
(Hours)

PBS

1
3
6
24

4.62 ± 0.04A
4.53 ± 0.05A
4.45 ± 0.11A
4.43 ± 0.06A

a

Malic acid
(pH 3.0)
4.54 ± 0.04A
4.28 ± 0.11A
3.61± 0.25B
0D

Blueberry
Juice
(pH 2.8)
4.45 ± 0.10A
3.26 ± 0.04B
2.72 ± 0.34C
0D

Blueberry
Juice
(pH 7.0)
4.55 ± 0.15A
4.53 ± 0.05A
4.39 ± 0.18A
4.20 ± 0.17A

Different letters denote significant differences when compared between each column (p<0.05). Detection limit for the assay is 2 log PFU/ml
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Chapter 3 Blueberry proanthocyanidins against human enteric
viruses in model foods and simulated gastric conditions
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Abstract
Blueberry proanthocyanidins (B-PAC) are known to decrease foodborne virus titers. The
application of B-PAC as therapeutic or preventive options against foodborne viral illness needs
to be determined using model foods and simulated gastric conditions in vitro. The objective of
this study was to evaluate the antiviral effect of B-PAC in model foods (apple juice; AJ and 2%
reduced fat milk) and simulated gastrointestinal fluids against human norovirus surrogates (feline
calicivirus; FCV-F9 and murine norovirus; MNV-1), hepatitis A virus (HAV) and Aichi virus
(AiV) over 24 h at 37oC. Equal amounts of each virus (5 log PFU/ml) were individually mixed
with either B-PAC (1, 2 and 5 mg/ml) made in AJ or 2% milk or simulated intestinal fluid
controls or controls including phosphate buffered saline or malic acid (pH 7.2) or apple juice or
2% milk over 24h at 37oC. All tested viruses were reduced to undetectable levels within 15 min
with B-PAC (1, 2 and 5 mg/ml) in AJ (pH 3.6). B-PAC activity was reduced in milk, where
significant reduction in titers were obtained only after 24 h. FCV-F9 was reduced by 0.4 and
1.09 log PFU/ml with 2 and 5 mg/ml, respectively and MNV-1 titers were reduced by 0.81 log
PFU/ml with 5 mg/ml after 24 h in milk. For HAV, reductions of 0.54 and 0.83 log PFU/ml with
2 and 5 mg/ml, respectively after 24 h in milk were obtained. With AiV, reductions of 0.52 and
0.84 log PFU/ml were obtained with 2 and 5 mg/ml after 24h. B-PAC at 5 mg/ml in simulated
intestinal fluid reduced titers of all four tested viruses to undetectable levels within 30 min.
Overall, these results show potential for B-PAC as preventive and therapeutic options for
foodborne viral illnesses.
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Introduction
Foodborne enteric viruses are commonly associated with non-bacterial acute gastroenteritis in
humans (1). Epidemiologically significant foodborne diseases include human noroviruses,
hepatitis A virus, rotaviruses, Aichi virus, hepatitis E virus, adenoviruses, sapovirus, astrovirus,
parvoviruses and other enteroviruses (2). However, some of these viruses such as human
norovirus and Aichi virus do not have vaccines available for their control. Natural plant extracts
have been used for their valuable medicinal properties since centuries (3). Extracts from plant
and fruit sources are known to contain abundant secondary metabolites mainly phenolic
compounds including but not limited to anthocyanidins, proanthocyanidins, catechins,
epicatechin gallate and tannins (3). Plant extracts are being studied extensively as sustainable
sources of potential therapeutic options, due to their low cost and consumer appeal (4). Among
the array of potential health benefits, these extracts are being screened for their antiviral potential
as well (3, 4).
In absence of specific treatment strategies or control measures for many of these viruses,
natural extracts provide novel alternatives to control of their spread and prevent their
transmission. Blueberries have gained increasing popularity for consumption due to their
associated broad spectrum of health benefits in the prevention of cardiovascular disorders and
age-induced oxidative stress, combined with antioxidative, anti-inflammatory, anti-carcinogenic,
neuro-protective, cardio-protective, antibacterial, and antiviral properties (5). Blueberries contain
polyphenols including anthocyanins, flavonoids and proanthocyanidins (PAC) (6). Our lab has
recently reported the antiviral effects of blueberry juice and blueberry juice proanthocyanidins
(B-PAC) against human norovirus surrogates and hepatitis A virus at 37oC in vitro. However, for
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B-PAC to be used as a therapeutic antiviral agent, its effectiveness in complex food matrices and
gastrointestinal fluids that mimic digestion needs to be evaluated. It is well known that the
effectiveness of antimicrobials decrease in the presence complex food matrices. Food
components such as carbohydrates, lipids, proteins, salts, or other acidic or alkaline conditions
may affect the antimicrobial properties of a given compound (7-14). Apple juice and milk have
been used extensively as model food systems in various studies that evaluated efficiency of
antimicrobials in food environments (7, 14, 15). With this information, the objective of this study
was to assess the antiviral effects of B-PAC in model food systems (apple juice and 2% reduced
fat milk) and in simulated gastrointestinal fluids against human noroviruses (using cultivable
surrogates such as feline calicivirus (FCV-F9) and murine norovirus (MNV-1)), hepatitis A virus
(HAV) and Aichi virus (AiV) over 24h at 37oC.

Materials and methods
Viruses and host cell lines
Feline calicivirus (FCV-F9) and host Crandell Reese Feline Kidney (CRFK) cells were
purchased from ATCC (Manassas, VA). Murine norovirus (MNV-1) was kindly gifted by Dr.
Skip Virgin (Washington Univ., St. Louis, MO) and RAW 264.7 cells were obtained from the
University of Tennessee at Knoxville. Hepatitis A virus (HAV; strain HM175) and fetal rhesus
monkey kidney (FRhK4) cells were provided by our collaborator, Dr. Kalmia Kniel (University
of Delaware). Aichi virus (AiV) was kindly provided by Dr. David Kingsley (USDA ARS,
Delaware) and propagated using host Vero cells. Host cell lines were maintained using
Dulbecco’s Modified Eagle’s Medium/Ham’s F-12 (DMEM-F12; HyClone Laboratories, Logan,
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UT) containing 2 or 10% heat-inactivated fetal bovine serum (FBS, HyClone Laboratories) and
1x Anti-Anti (Antibiotic-Antimycotic, Invitrogen, Grand Island, NY) at 37ºC in an atmosphere
containing 5% CO2 as described earlier (16).
Assessment of antiviral activity in model food systems
Each virus was individually mixed with equal amounts of treatments that included B-PAC (2, 4
and 10 mg/ml dissolved in either apple juice (pH 3.6) or 2% milk to obtain a final titer of ~5 log
PFU/ml. Controls included each individual virus mixed in apple juice (AJ; pH 3.6) or 2% milk or
malic acid (pH 3.0) to obtain a final titer of ~5 log PFU/ml. Treatments were incubated at 37ºC
over 5, 15, 30, 60, 120, 180, 360 min or 24h and stopped/neutralized by adding to cell-culture
media containing 10% heat-inactivated fetal bovine serum (FBS), followed by serial dilutions in
cell-culture media containing 2% FBS. The infectivity of the viruses was evaluated using
standard plaque assays as described before (17). Each experiment was replicated thrice and
assayed in duplicate.
Antiviral activity under simulated gastrointestinal conditions
Equal amounts of viruses at (~6 log PFU/ml) were mixed in a ratio of 1:10 of with phosphate
buffered saline (PBS; 7.2 as control) or malic acid control (pH 1.5) or simulated intestinal fluid
(SIF; pH 7.5, obtained from Fisher Scientific, USA, Waltham, MA, USA), simulated gastric
fluid (SGF; pH 1.5, obtained from Fisher Scientific, USA, Waltham, MA, USA), or B-PAC (5
mg/ml) made in SIF or SGF and incubated at 37ºC for 1, 3, 6 and 24 h. Sodium carbonate
(Na2CO3; 200mM) was used to neutralize the reaction mixture as described earlier and followed
by serial dilution in cell-culture media containing 2% FBS (18). Virus infectivity was evaluated
using standard plaque assays that were carried out in duplicates and replicated thrice.
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Statistical analysis
Data obtained from the three replications for each individual virus were statistically analysed
using ANOVA with SAS software (version 9.3, SAS Institute, Cary, NC, USA) and Tukey’s test
using a completely randomized design model as described in previous studies to determine
statistically significant differences between the viral titers recovered from treatments and
controls.
Results
Antiviral activity in model food systems
Antiviral activity of B-PAC was shown to be the highest when prepared in apple juice (pH 3.6).
FCV-F9 titers were reduced to undetectable levels (< 2 log PFU/ml; limit of detection of the
assay) within 15 min at 37oC with 1, 2 and 5 mg/ml of B-PAC (Table 1a). However, the antiviral
activity was impeded to a large extent when B-PAC was made in 2% reduced fat milk. Titer
reductions of 0.40±0.03 and 1.12±0.01 log PFU/ml were obtained after 24h with 1, 2 and 5mg/ml
respectively. After 6h of treatment, reductions of 0.33±0.05, 0.44±0.16 log PFU/ml were
obtained with 2 and 5mg/ml respectively (Table 3.1). The milk control caused a reduction of
0.96±0.23 log PFU/ml after 24 h (Table 3.2).
MNV-1 showed a similar trend, where reduction to undetectable levels was obtained
when B-PAC was prepared in AJ with all three concentrations (1, 2 and 5 mg/ml) within 15 min
(Table 3.3). However, when treated with B-PAC in 2% milk, minor reductions of 0.18±0.01 and
0.05±0.02, PFU/ml were obtained after 6h with 2 and 5 mg/ml, respectively and 0.81±0.18 log
PFU/ml after 24h with 5 mg/ml (Table 3.4).
B-PAC prepared in AJ caused HAV titers to reduce to undetectable levels within 15 min with 1,
2 and 5 mg/ml (Table 3.5). When B-PAC was prepared in 2% milk, reductions of 0.54±0.15 and
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0.83±0.04 log PFU/ml were obtained after 24h treatment with 2 and 5 mg/ml concentration of BPAC. After 6h of treatment, reductions of 0.15±0.01 and 0.13±0.02 log PFU/ml were obtained
for 2 and 5 mg/ml B-PAC (Table 3.6).
B-PAC made in AJ had increased antiviral activity where reduction to undetectable levels
(< 2 log PFU/ml) was obtained after treatment with 2 and 5 mg/ml B-PAC in AJ after 30 min at
37oC. However, the AJ control by itself did not cause any significant change in titers after 3 h of
treatment (Table 3.7). Reduced antiviral activity of B-PAC was seen when prepared in 2%
reduced fat milk, where titer reductions of 0.14±0.01, 1.4±0.14, 0.84±0.03 log PFU/ml were
obtained with 5 mg/ml B-PAC in milk after 3, 6 and 24 h. Reductions of 0.29±0.01, 0.39±0.19
and 0.52±0.17 were obtained with 2 mg/ml B-PAC in milk after 3, 6 and 24 h. The milk control
caused a reduction of 0.48±0.19 log PFU/ml after 24 h (Table 3.8). No significant reduction with
B-PAC in milk at any concentration was obtained with 1 or 3h treatment for FCV-F9, MNV-1,
HAV or AiV. Moreover the AJ control did not change titers of the four tested viruses over 3h.
Antiviral activity under simulated gastrointestinal conditions
Simulated gastric fluid (SGF; pH 1.5) experiments were not conducted with FCV-F9 given its
sensitivity to low pH (19). MNV-1, HAV and AiV did not survive in the SGF control; hence the
treatments with B-PAC under gastric conditions were inconclusive. With SIF (pH 7.5), B-PAC at
5 mg/ml reduced titers of all four tested viruses within 30 min (Table 3.9).
Discussion
B-PAC and BJ have been shown to be highly effective in reducing the titers of all the four tested
viruses when made in 10% ethanol where the antiviral activity was found to be both time and
concentration dependent. However, for potential application of B-PAC as an antiviral
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therapeutic, evaluating its activity in model food systems and gastrointestinal conditions is
necessary. Amid the two food systems, the effectiveness of treatments was seen to be higher in
AJ compared to the effects of B-PAC in 10% ethanol, where higher titer reductions in lesser time
were obtained. For instance, MNV-1 titers were reduced to undetectable levels after 3h with 5
mg/ml B-PAC, however when 5 mg/ml B-PAC was made in AJ, similar reduction was obtained
within 15 min. When tested as a control, AJ at pH 3.6 alone did not cause any significant
reduction in titers over 3h for all four viruses. These observations suggest that the enhanced
antiviral activity of B-PAC in AJ could be a synergistic effect of PAC together with the low pH
of AJ as well as the presence of polyphenols like hydroxycinnamic acid and chlorogenic acid in
AJ (20).
Previous research carried out to test effectiveness of antimicrobials in food systems points to
similar observations. A study examined the antimicrobial effect of seaweed Himanthalia
elongata in carbohydrate (glucose) and protein (bovine serum albumin) model food systems
against Salmonella abony and Listeria monocytogenes (21). The extract at concentration of 8
mg/ml was shown to cause 100% inhibition of both Salmonella abony and L. monocytogenes
after 24h at 37oC. The efficacy was reported to be dose dependent with lower concentration of 2
mg/ml causing only 48.4% inhibition and no inhibition at 1 mg/ml. In protein system, 100%
inhibition for both organisms was reported at 8 mg/ml extract and lower inhibition with lower
concentrations. An interesting observation reported by the study was that the antimicrobial
efficacy of the extract increased with increasing concentration of glucose, which was attributed
to a possible synergistic effect where glucose can lower water activity restricting microbial
growth.
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When B-PAC was prepared in 2% milk, a sharp decline in effectiveness was seen where
significant titer reductions were obtained only after 24h of treatment for all tested viruses.
Similar results were demonstrated in a previous study where grape seed extract in the presence of
bovine serum albumin (0.3 g/liter) was reported to have reduced antiviral activity against MNV1, implying that organic load such as protein interferes with the effectiveness of treatments (22).
In this study too, reduced activity with increasing organic load was observed in model food
systems. This could possibly be due to the inhibition from the carbohydrates, lipids and proteins
present in the milk matrix. Peppermint oil and eugenol were tested in a study for their
antimicrobial activity against Bacillus cereus, Staphylococcus aureus, and Escherichia coli in
model food systems. In cabbage and barley model systems, significant reduction was reported
for all four organisms with 0.4 % and 0.4% concentration after 28 days of storage at 37oC (23).
In another study, cinnamon bark essential oil at 1,000 was shown cause a 1 log CFU/ml
reduction of L. monocytogenes in whole milk as compared to 3 log CFU/ml reduction in
skimmed milk indicating that higher fat content can hamper the antimicrobial effect (14). In the
present study, 2% milk control was seen to cause a reduction of 0.96 and 0.46 log PFU/ml in
FCV-F9 and AiV titers after 24 h. Previous studies have shown that milk components like
lactoferrin can inhibit adsorption of hepatitis C virus (HCV) to host cells by binding to the
envelope proteins E1 and E2 (24, 25). Similarly, lactoferrin was reported to inhibit adsorption of
rotavirus to its host cells by binding to the virus particle (26). Lactoferrin was also reported to
inhibit entry of poliovirus into host cells by blocking of receptors (27). However, lactoferrin
might lose some of its activity after pasteurization. Thus if B-PAC is prepared in a food matrix
that has inherent antiviral activity, synergistic effects can be further exploited to make it a better
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antiviral alternative. B-PAC can be encapsulated or nano-emulsions can be developed using
conjugates such as sodium caesinate for better dispersion and solubility. In a study, sodium
caesinate encapsulated thymol was shown to have better dispersion properties and significantly
higher antimicrobial activity against L. monocytogenes in milk as compared to the free thymol
(28). The conjugate was shown to be stable at neutral pH, however at pH of 4.6, soybean
polysaccharide was used for preventing aggregation. Similar approach could be used to develop
B-PAC as an antiviral therapeutic thus helping it retain its antiviral activity even in presence of
food matrices.
To be able to exploit antiviral properties of B-PAC, it is particularly important to study its
effect under conditions that it will possibly encounter during consumption. Furthermore, it is also
important that the antiviral effects of the said therapeutic be maintained in the low pH and
conditions of the gastrointestinal tract. Both SGF and SIF were chosen to study effect of
treatment under different pH conditions (pH of SIF is 1.5 and pH of SGF is 7.5) and gut enzymes
like pepsin and pancreatin, as they would be subject in vivo. However, the tested viruses did not
survive in the simulated gastric fluid (pH 1.5). This could possibly be due to the fact that MNV-1
as a human norovirus surrogate was used and it could not mimic the survival of human norovirus
at such low pH. The same could be true with HAV, since the strain HM175 used in the study is a
lab-adapted strain that did not respond to the low pH in a manner similar to the wild type strain.
Another possible reason for their survival in vivo could also be due to their binding to mucus or
protection from food during the stomach transit, so they are protected from the enzymatic
environment. Antimicrobial activity of T. camphoratus crude methanolic and water extract
(minimum inhibitory concentration of 2 mg/ml) at 37oC after 24h was reduced after exposure to
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simulated gastric fluid (29). The study suggested that exposure to gastric fluid caused chemical
alteration or degradation of the active compounds leading to decreased antimicrobial activity. In
this study, since the viruses did not survive in the gastric fluid, it was difficult to conclude the
fate of B-PAC upon exposure to gastric environment.
This study will help provide a better understanding on the effective optimum
concentration levels and time required to inactivate the target viruses for use as antiviral therapy.
The reported results might be able to provide useful data for designing where time-release or
dosage for these antiviral compounds. Additionally, animal feeding studies with blueberries and
B-PAC using pre- and post-challenge should be carried out to determine antiviral effects. In
addition, “omics” approaches (metagenomic analysis and next generation sequencing) can be
used to determine changes in the gut microbiota that could enhance growth of beneficial
microflora to prevent gastrointestinal disease. However, before any recommendations for
consumption as therapeutic options can be suggested or health claims made, clinical trials and
regulatory approvals will be needed and hence in vitro data must be interpreted with caution as
indicated in earlier reports (30).
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Appendix C
Table 3.1 Effect of blueberry proanthocyanidins (B-PAC) in apple juice (AJ) on FCV-F9 titers over 3h at 370C

Time
(min)

PBSa
(pH 7.2)

15
30
60

4.79 ± 0.14 A
4.83 ± 0.05A
5.03 ± 0.06A

Recovered titer (Log PFU/ml)
B-PAC in B-PAC in
AJ
AJ
AJ
(pH 3.6)
(1 mg/ml) (2 mg/ml)
0 *B
0 *B
4.70 ± 0.10 A
*B
0
0 *B
4.88 ± 0.05 A
0 *B
0 *B
4.86 ± 0.06 A

B-PAC in
AJ
(5 mg/ml)
0 *B
0 *B
0 *B

a - phosphate buffered saline; * - Detection limit of the assay is 2 log PFU/ml. Within each column for each virus, different letters denote significant differences
between treatments (P < 0.05).

Table 3.2 Effect of blueberry proanthocyanidins (B-PAC) in 2% milk on FCV-F9 titers over 24h at 370C
Recovered titer (Log PFU/ml)
Time
(Hours)

PBSa

3
6
24

4.85 ± 0.05A
4.99 ± 0.07A
4.75 ± 0.07 A

2% Milk

B-PAC in 2%
Milk
(2 mg/ml)

B-PAC in 2%
Milk
(5 mg/ml)

4.10 ± 0.02 AB
4.10 ± 0.05 AB
3.79 ± 0.30 B

4.76 ±0.02 A
4.66 ±0.12 A
4.35 ±0.10 A

4.67 ±0.11 A
4.55 ±0.23 A
3.66 ± 0.06 B

a - phosphate buffered saline; * - Detection limit of the assay is 2 log PFU/ml. Within each column for each virus, different letters denote significant differences
between treatments (P < 0.05).
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Table 3.3 Effect of blueberry proanthocyanidins (B-PAC) in apple juice (AJ) on MNV-1 titers over 3h at 370C
Recovered titer (Log PFU/ml)
Time
(min)

PBSa
(pH 7.2)

AJ
(pH 3.6)

B-PAC in
AJ
(1 mg/ml)

B-PAC in
AJ
(2 mg/ml)

B-PAC in
AJ
(5 mg/ml)

15
30
60

4.74 ± 0.24 A
4.89 ± 0.08A
4.84 ± 0.10A

4.76 ± 0.19 A
4.76 ± 0.19 A
4.76 ± 0.19 A

0 *B
0 *B
0 *B

0 *B
0 *B
0 *B

0 *B
0 *B
0 *B

a - phosphate buffered saline; * - Detection limit of the assay is 2 log PFU/ml. Within each column for each virus, different letters denote significant differences
between treatments (P < 0.05).

Table 3.4 Effect blueberry proanthocyanidins (B-PAC) in 2% milk on MNV-1 titers over 24h at 370C
Recovered titer (Log PFU/ml)
Time
PBSa
(Hours)
3
6
24

4.90 ± 0.10 A
4.75 ± 0.07A
4.50 ± 0.07A

2% Milk

B-PAC in 2%
milk
(2 mg/ml)

B-PAC in 2%
milk
(5 mg/ml)

4.92 ± 0.02 A
4.94 ± 0.02 A
4.91 ± 0.01 A

4.51 ± 0.07 A
4.57 ± 0.06 A
4.66 ± 0.04 A

4.53 ± 0.09 A
4.80 ± 0.05 A
3.69 ± 0.25 B

a - phosphate buffered saline; * - Detection limit of the assay is 2 log PFU/ml. Within each column for each virus, different letters denote significant differences
between treatments (P < 0.05).
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Table 3.5 Effect of blueberry proanthocyanidins (B-PAC) made in apple juice (AJ) on HAV titers over 3h at 370C
Recovered titer (Log PFU/ml)
Time
(min)

PBS
(pH 7.2)

AJ
(pH 3.6)

15
30
60

5.09 ± 0.04 A
4.81 ± 0.05A
4.78 ± 0.03A

4.87 ± 0.05 A
4.86 ± 0.06 A
4.70 ± 0.05 A

B-PAC in
AJ
(1 mg/ml)
0 *B
0 *B
0 *B

B-PAC in
AJ
(2 mg/ml)
0 *B
0 *B
0 *B

B-PAC in
AJ
(5 mg/ml)
0 *B
0 *B
0 *B

a - phosphate buffered saline; * - Detection limit of the assay is 2 log PFU/ml. Within each column for each virus, different letters denote significant differences
between treatments (P < 0.05).

Table 3.6 Effect of blueberry proanthocyanidins (B-PAC) made in 2% milk on HAV titers over 24h at 370C
Recovered titer (Log PFU/ml)
Time
(hours)

PBSa

3
6
24

5.09 ± 0.04 A
4.90 ± 0.05A
4.98 ± 0.08 A

2% Milk

B-PAC in 2%
milk
(2mg/ml)

4.87 ± 0.05 A
4.76 ±0.07 A
4.67 ± 0.14 A

4.87 ± 0.03 A
4.75 ± 0.04 A
4.44 ± 0.23 A

B-PAC in 2%
milk
(5mg/ml)
4.80 ± 0.08 A
4.77 ± 0.07 A
4.15 ± 0.12 B

a - phosphate buffered saline; * - Detection limit of the assay is 2 log PFU/ml. Within each column for each virus, different letters denote significant differences
between treatments (P < 0.05).
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Table 3.7 Effect of blueberry proanthocyanidins (B-PAC) prepared in apple juice (AJ) on Aichi virus (AiV) at ~ 5 log PFU/ml
over 24h at 37oC
Recovered titer (Log PFU/ml)
Time
(Hours)

PBSa
(pH 7.2)

AJ
(pH 3.6)

NAJ
(pH 7.0)

0.5
1
3

4.79 ± 0.14A
4.75 ± 0.07 A
4.53 ± 0.05 A

4.70 ± 0.10 A
4.80 ± 0.10 A
4.56 ± 0.22 A

4.49 ± 0.09 A
4.42 ± 0.04 A
4.42 ± 0.15 A

Blueberry
PAC in AJ
(1 mg/ml)
0*B
0*B
0*B

Blueberry
PAC in AJ
(2 mg/ml)
0*B
0*B
0*B

Table 3.8 Effect of blueberry proanthocyanidins (B-PAC) prepared in 2% milk on Aichi virus (AiV) over 24h at 37oC
Recovered titer (Log PFU/ml)
Time
(Hours)
3
6
24

PBSa

2% Milk

Blueberry
PAC in 2%
Milk
(2 mg/ml)

4.60 ± 0.13A
4.58 ± 0.30A
4.43 ± 0.05A

4.35 ± 0.05A
4.13 ± 0.02A
3.95 ± 0.24B

4.31 ± 0.12A
4.19 ± 0.11A
3.91 ± 0.22B

Blueberry
PAC in 2%
Milk
(5 mg/ml)
4.46 ± 0.11A
3.18 ± 0.16C
3.59 ± 0.08B
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Table 3.9 Effect of B-PAC (5 mg/ml) prepared in simulated gastric fluid (SGF) and simulated intestinal fluid (SIF) against
FCV-F9, MNV-1, HAV and AiV (~ 5 log PFU/ml) over 1 h at 37ºC
Virus

FCV-F9

MNV-1

HAV

AiV

Treatment
PBSa (pH 7.2)
SIF (pH 7.5)
B-PAC in SIF
PBSa (pH 7.2)
SIF (pH 7.5)
SGF (pH 1.5)
B-PAC in SIF
a
PBS (pH 7.2)
SIF (pH 7.5)
SGF (pH 1.5)
B-PAC in SIF
PBSa (pH 7.2)
SIF (pH 7.5)
SGF (pH 1.5)
B-PAC in SIF

Time in hours
0.5
1
Recovered titer (Log PFU/ml)
4.76 ± 0.06 A
4.80 ± 0.03 A
4.79 ± 0.25 A
4.79 ± 0.25 A

0 *B

0 *B

4.95 ± 0.07 A
4.84 ± 0.09 A

4.95 ± 0.07 A
4.77 ± 0.09 A

0 *B
0 *B

0 *B
0 *B

4.77 ± 0.01 A
4.61 ± 0.01 A

4.78 ± 0.047A
4.50 ± 0.03 A

0 *B
0 *B

0 *B
0 *B

4.79 ± 0.14A
4.41 ± 0.05A
0 *B

4.75 ± 0.07A
4.44 ± 0.21A
0 *B

0 *B

0 *B

a - phosphate buffered saline; * - Detection limit of the assay is 2 log PFU/ml. Within each column for each virus, different letters denote significant differences
between treatments (P < 0.05).
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Abstract

Blueberry polyphenols have demonstrated effective antiviral properties against cultivable human
norovirus surrogates, Aichi virus, and hepatitis A virus. The objectives of this study were to (a)
compare the antiviral activity of the monomeric catechin monohydrate, procyanidin B2, B-type
PAC from blueberries (B-PAC) and A-type PAC from cranberries (C-PAC) against hepatitis A
virus (HAV), Aichi virus (AiV) and the cultivable human norovirus surrogates, feline calicivirus
(FCV-F9) and murine norovirus (MNV-1) at 37ºC by plaque assays; (b) determine the effect of
blueberry proanthocyanidins (B-PAC) on viral adsorption and viral replication of HAV, AiV,
FCV-F9 and MNV-1 at 37ºC using plaque assays; (c) determine effects of B-PAC on virus
structure using Transmission Electron Microscopy (TEM) and enzyme linked immunosorbent
assays (ELISA). Experiments were carried out in duplicate, replicated thrice, and data were
analyzed statistically analyzed. Monomeric catechins at 1 mg/ml reduced FCV-F9 titers to
undetectable levels within 1 h and MNV-1 after 24h, AiV by 0.66 log PFU/ml after 24h, without
any significant effect on HAV. Procyanidin B2 at 1 mg/ml reduced FCV-F9 to undetectable
levels after 3h, with 1.23, 0.04 and 0.67 log PFU/ml reduction for MNV-1, HAV and AiV after
24h. Pre-treatment of host cells with 0.5 mg/ml B-PAC showed that FCV-F9, MNV-1, HAV and
AiV titers were reduced by 0.63, 0.53, 0.34 and 0.62 log PFU/ml indicating that B-PAC had
modest effects on preventing viral adsorption. However, lower reduction after post-infection
treatment was obtained. TEM observations revealed moderate effect on the structure of the viral
particles with either damaged viral capsid or binding by PAC, possibly preventing their
attachment to host cells. These results provide insights for use of blueberry polyphenols in
developing preventive antiviral therapies.
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Introduction
With the rise in number of foodborne diseases caused by enteric viruses, there is a need to
develop effective mitigation strategies for their control. In the current absence of vaccination or
effective treatment options for human norovirus infections, natural alternatives are being
evaluated (1). Plant derived polyphenols and their associated health benefits as antimicrobials
against bacteria are well established (2-5). Likewise, blueberries are known to have a broad
spectrum of health benefits such as prevention of cardiovascular disorders, age-induced oxidative
stress, inflammatory responses, and diverse degenerative diseases along with anti-carcinogenic,
neuro-protective, cardio-protective, antibacterial, and antiviral properties (6). Blueberries contain
polyphenols including anthocyanins, flavonoids and proanthocyanidins (PAC), also referred to as
condensed tannins (7). Tannins (condensed and hydrolysable) differ from other phenolic
compounds for they are able to precipitate proteins, known as astringency (8). PAC’s are dimers,
oligomers, and polymers of catechins bound together by linkages between C4 and C8 (or C6)
where the monomeric flavanols differ in the stereochemistry of C-3 and their hydroxylation
pattern in ring A and B (9). Many plant foods, including blueberries, apples and grapes contain
high amounts of PACs, but only a few contain A-type PACs (10). The polymerized PACs in
blueberries contain A-type linkages, with different profiles and amounts as compared to
cranberries (11). Cranberries contain PAC’s with A-type linkage accounting for 51– 91% of total
PACs (10). B-type proanthocyanidins can be converted to A-type proanthocyanidins by radical
oxidation (12) Distinction between A- and B-type PAC structures is of importance because the
difference can influence their biological properties. The A-type PACs exhibit significantly
greater inhibition of adhesion of P-fimbriated Escherichia coli to uroepithelial cells in vitro than
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the B-type PACs, which is the initial step in the development of urinary tract infection (UTI)
(13). Blueberries have been known to contain around 88-261 mg of proanthocyanidin/100 gram
of edible portion as per the USDA database for flavonoid content (USDA Database for the
proanthocyanidin Content of Selected Foods, August 2004). The recommended dose for
blueberries in daily diet can be 1 to 2 cup serving of fresh or frozen blueberries per day, and
consumption of more than 100 gram fruit per day may be required for health benefits. The
blueberry PAC concentration range used in our study is from 1 to 5 mg/ml that compares to
eating about ¼ of the daily serving size.
Several attempts have been made at understanding the mode of antiviral action of natural
plant polyphenols against human noroviral (HNoV) surrogates, feline calicivirus (FCV-F9),
murine norovirus (MNV-1) using various techniques such as electron microscopy studies,
binding studies, molecular assays and in vitro cell culture assays (4, 14, 15). Viruses are known
to cross the host epithelial barrier through attachment to carbohydrate moieties of host cell
glycoproteins, glycolipids such as sialic acid, and proteoglycans (16). Human noroviruses in
addition to binding to histo-blood group antigens are also known to bind to porcine gastric mucin
(PGM) (17). PGM has been used widely in studies to discriminate between infectious and noninfectious norovirus particles (18). ELISA (enzyme-linked immune sorbent assay) involving
differential binding of viral particles with intact and non-intact capsid to PGM has been used to
determine viral infectivity (Hirneisen and Kniel, 2012). Briefly, only those viruses that have an
intact capsid after inactivation treatments will bind to the PGM in the assay. The study assessed
attachment of MNV-1 after heat, high-pressure, ozone and UV inactivation treatments, and
found that only heat treatments at 80 and 100oC for 5 min caused a significant change in the
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binding ability whereas other treatment did not have a significant effect on the capsid (19).
Saliva-binding ELISA showed that grape seed extract (GSE) treatments of 0.2 and 2 mg/ml at
37°C for 1 h caused a significant difference in the binding ability of HNoV’s, indicating that loss
of infectivity caused by GSE treatments was due to capsid damage and thus loss in binding
ability (4). Similar approaches could be used for determining the mechanism of action of
blueberry juice (BJ) and B-PAC on foodborne viruses. Such assays would be useful in
understanding the effect of treatments on capsid integrity/structure and thereby their decrease
binding abilities. Correlation between binding studies, infectious plaque assays and TEM
analysis could help elucidate the exact mechanism of action of these polyphenols against these
viruses.
The objectives of this study were to (a) compare the antiviral activity of the monomeric
unit (Catechins) and dimeric procyanidin B2 (B- type PAC present in blueberries) to PAC in
blueberries (B-PAC, previously published data) on infectivity of hepatitis A virus (HAV), Aichi
virus (AiV) and human norovirus surrogates, FCV-F9 and MNV-1 at 37ºC; (b) determine the
effect of blueberry juice (BJ) and blueberry proanthocyanidins (B-PAC) on viral adsorption and
viral replication of HAV, AiV, FCV-F9 and MNV-1 at 37ºC and (c) determine effects of B-PAC
on virus structure using Transmission Electron Microscopy and ELISA.

Materials and Methods
Viruses and cell lines
Feline calicivirus (FCV-F9) and host Crandell Reese Feline Kidney (CRFK) cells were
purchased from ATCC (Manassas, VA). Murine norovirus (MNV-1) was kindly gifted by Dr.
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Skip Virgin (Washington Univ., St. Louis, MO) and RAW 264.7 cells were obtained from the
University of Tennessee at Knoxville. Hepatitis A virus (HAV; strain HM175) and fetal rhesus
monkey kidney (FRhK4) cells were provided by our collaborator, Dr. Kalmia Kniel (University
of Delaware). All three host cell lines were maintained using Dulbecco’s Modified Eagle’s
Medium/Ham’s F-12 (DMEM-F12; HyClone Laboratories, Logan, UT) containing 10% heatinactivated fetal bovine serum (FBS, HyClone Laboratories) and 1x Anti-Anti (AntibioticAntimycotic, Invitrogen, Grand Island, NY) at 37ºC in an atmosphere containing 5% CO2. Aichi
virus (AiV) was kindly provided by Dr. David Kingsley (USDA ARS, Delaware). Host Vero
cells were maintained in Dulbecco’s Modified Eagle’s Medium/Ham’s F-12 (DMEM-F12;
HyClone Laboratories, Logan, UT) with 2% FBS heat-inactivated fetal bovine serum (FBS,
HyClone Laboratories) and 1x Anti-Anti (Antibiotic-Antimycotic, Invitrogen, Grand Island, NY)
at 37ºC in an atmosphere containing 5% CO2 as described earlier (20).
Comparison of antiviral activity of components and types of PAC’s
Antiviral activity of catechin hydrate (Sigma Aldrich) and procyanidin B2 (Sigma Aldrich)
against the four viruses; FCV-F9, MNV-1, HAV and AiV was compared to the antiviral activity
of PAC’s isolated from blueberries (B-type PAC; kindly provided as a gift by Dr. Amy Howell,
Rutgers University) and cranberries (A-type PAC; previously published data;(21)). Equal
amounts of each virus at 5 log PFU/ml were mixed with equal amounts of catechin hydrate (10
or 2 mg/ml), procyanidin B2 (1 or 0.5 mg/ml), or B-PAC (all three were in powder form and
were dissolved in 10% ethanol) and treated for 3, 6 and 24 h at 37oC. Reactions were stopped in
DMEM containing 10% FBS and serially diluted in DMEM with 2% FBS. Viral infectivity was
evaluated using standardized plaque assays (20, 21).
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Effect of B-PAC and BJ on host cells lines
Cytopathic effects of B-PAC, BJ (pH 2.8) and NBJ (neutralized blueberry juice; pH 7.0)
treatments on the host cell lines were also determined. The maximum concentration of B-PAC
used in the viral treatment and assays was 5 mg/ml, however, the host cell lines were only
exposed to a maximum 20-fold dilution of the treatment after neutralization/stopping of
treatment. Thus, each individual cell lines were exposed to B-PAC at 0.5 mg/ml and BJ and NBJ
for 2h at 37oC and observed under optical microscope to determine visible changes.
Effect of B-PAC and BJ on adsorption and replication
To determine the effect of B-PAC and NBJ on viral replication, host CRFK, RAW 264.7,
FRhK4, and Vero cells in 6-well plates were first infected with FCV-F9, MNV-1, HAV, and
AiV respectively for 2 h, followed by treatment with B-PAC (0.5mg/ml) or NBJ for 20 min at
37°C. To determine effects on viral adsorption/binding, the host cells were pretreated with BPAC (0.5 mg/ml) or NBJ for 20 min, followed by viral infection for 2 h at 37°C. Cells were then
overlaid with complete DMEM containing 0.75% or 1% agarose. After incubation for 2 to 8 days
at 37°C under 5% CO2, a second overlay containing neutral red was added followed by
incubation to allow the visualization of plaques and plaques were counted and recorded as plaque
forming units (PFU/ml) (21).
Transmission electron microscopy (TEM) analysis
FCV-F9, MNV-1, HAV or AiV at ~6.5 log PFU/ml were mixed with equal volumes of B-PAC (2
mg/ml), BJ, or sterile distilled water (control) and the individual viruses were incubated at 37oC
for 15 min, 1 h, 30 min and 1 h respectively (based on reduction of viral titers obtained with
treatments). Fresh glow discharged, formvar and carbon coated copper grids were coated with
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10-l of the viral samples, stained with uranyl acetate for 1 min and allowed to dry. The samples
were then observed under a Hitachi H800 at 75KeV (courtesy of Dr. Dunlap at the UT-Knoxville
Advanced Microscopy and Imaging Center).

ELISA PGM binding assay
The protocol for PGM binding ELISA was adapted from (19). ELISA plates pre-coated with
poly-D-lysine (ThermoFisher Scientific) were coated with 100 μl of porcine gastric mucin
(Sigma) at 10 μm/mL in Tris Buffered Saline (TBS; pH 7.6) and were incubated for 24h at 4oC.
Plates were washed with deionized double distilled (dDI) water thrice to remove unbound
material. Following this, the plates were blocked with Animal-Free Blocking Buffer (Vector
Labs, Burlingame, CA) for 2 h at room temperature. The wells were washed twice with dDI
water to remove excess blocking buffer. MNV-1 samples (treatment or control) diluted in TBS
(upto 5 serial dilutions) were added to the wells and were allowed to incubate at 37oC for 1 h.
Wells were washed thrice with dDI water followed by addition of 1:1000 dilution of monoclonal
anti-MNV IgA (gifted by Dr. Christiane Wobus, University of Michigan) diluted in TBS and
allowed to incubate at 37oC for 1 h. Unbound anti-MNV IgA was removed by washing the wells
with TBS with 0.05% Tween- 20 (TTBS). Horseradish peroxidase (HRP)-conjugated goat antimouse secondary IgA (diluted 1:5000 in TTBS) (KPL) was used for detection of bound primary
antibody followed by incubated at 37oC for 1 h. Unbound secondary antibody was removed by
washing thrice with TTBS followed by addition of 80 μL of 3,3’, 5, 5’ tetramethylbenzidine
(TMB) liquid substrate (Thermo Fisher) and incubation at room temperature for 10 min. The
reaction was stopped by the addition of 2M H2SO4 and absorbance was read at 450 nm.
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Statistical analysis
Statistical analysis was carried out using ANOVA with SAS software (version 9.3, SAS Institute,
Cary, NC, USA) and Tukey’s test on a completely randomized design with data obtained from
the three replications for each individual virus as described in previous studies (14, 22).
Results
Comparison of antiviral activity of monomeric and polymeric PAC’s
Polymeric B-PAC at 1 mg/ml was shown to reduce FCV-F9, MNV-1 and HAV titers to
undetectable levels within 3 h of treatment, while longer incubation time of 6h was needed to
reduce AiV titers to undetectable levels at 37oC. Monomeric catechins at 1 and 5 mg/ml reduced
FCV-F9 to undetectable levels after 6 and 3h, respectively. B-type PAC, procyanidin B2 at both
0.5 and 1 mg/ml reduced FCV-F9 to undetectable levels after 3h (Table 4.1). MNV-1, the
sturdier of the surrogates showed lower reduction with both monomeric catechin and procyanidin
B2. Reductions of 0.42±0.02 and 1.76±0.13 log PFU/ml were obtained for MNV-1 with 1 and 5
mg/ml monomeric catechin after 3h. MNV-1 titers reduced to undetectable levels after 6h with 5
mg/ml monomeric catechin and after 24h with 1 mg/ml monomeric catechin. No significant
reduction in MNV-1 titers was obtained with procyanidin B2, except with a reduction of
1.23±0.11 log PFU/ml after 24h with 1 mg/ml (Table 4.2). Similarly for HAV, no significant
reductions were obtained either with monomeric catechin or procyanidin B2 even after 24h
(Table 4.3). AiV titer reductions of 0.36±0.20, 0.88±0.0 and 0.95±0.04 log PFU/ml were
obtained with monomeric catechin at 5 mg/ml after 3, 6 and 24h, respectively. Monomeric
catechin at 1mg/ml reductions of 0.77±0.02, 0.82±0.01 and 0.66±0.19 log PFU/ml after 3, 6 and
24h respectively were obtained. Procyanidin B2 at 1 mg/ml had minimal effect on AiV titers,

127

with reductions of 0.41±0.21, 0.49±0.13 and 0.67±0.19 log PFU/ml and 0.23±0.04, 0.12±0.03
log PFU/ml with 5 mg/ml after 3, 6 and 24h respectively were obtained (Table 4.4).
Effect of B-PAC and BJ on host cells lines
B-PAC at a concentration of 0.5 mg/ml was not found to be cytotoxic to the four tested host cell
lines. Undiluted BJ when added directly to the host cells had some minor effects after 2h.
However, neutralized BJ (NBJ) did not show any morphological visual changes in the four host
cells and was used further in the time of addition experiments. In the experiment involving
treatment of viruses with B-PAC, the cells are exposed to a maximum of 20-fold diluted B-PAC
and hence the host cells do not show cytopathic/cytotoxic effects.
Effect of B-PAC and BJ on viral adsorption and viral replication
Treatment of host cells with 0.5 mg/ml B-PAC before viral infection reduced the titers of FCVF9, MNV-1, HAV and AiV by 0.63±0.01, 0.53±0.03, 0.34±0.07 and 0.62±0.34 log PFU/ml,
respectively (Table 4.5). When the cells were treated with 0.5 mg/ml B-PAC post viral infection,
reductions in viral titers of 0.37±0.01, 0.23±0.06, 0.03±0.01 and 0.30±0.07 log PFU/ml were
obtained for FCV-F9, MNV-1, HAV and AiV respectively (Table 4.6). These results suggest that
B-PAC at 0.5 mg/ml plays a modest effect in the prevention of virus attachment to the host and
adsorption with a lesser effect on inhibiting replication. NBJ did not have any significant effect
on viral adsorption or viral replication of all the four tested viruses.
Transmission electron microscopy studies using B-PAC
TEM studies were carried out with B-PAC (0.5 mg/ml) to elucidate the mechanism of action of
B-PAC on the virus structure. B-PAC was shown to encapsulate FCV-F9 viral particles while
some treated viruses also had structural damage with capsid disruption by TEM as shown (Fig 4
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– 1a and b). Similar results were observed with MNV-1 where the particles were coated or
adhered with the treatment material (Fig 4 – 2a and b), and similarly treated HAV samples
appeared to be coated/encapsulated by B-PAC compared to the water control (Fig 4- 3a and b).
However, TEM observations for AiV did not show any significant change in the viral particle or
damage to the capsid after B-PAC treatment (Fig 4, 4a and b).
ELISA binding study
The PGM coating on the plate led to a very high background, without any significant difference
between the controls and test wells. Further investigation revealed that the primary antibody
(IgA) bound unspecifically to the PGM resulting in detection even in control wells. Hence, no
conclusive results were obtained at this time while the screening for additional specific
antibodies continues to be researched.
Discussion
As there are an increasing number of studies that examine antiviral properties of natural
polyphenols, it is equally important to assess them in terms of their antiviral potential, compare
their effect when these polymeric PAC’s are isolated from different sources and when used as
individual monomeric units. One of the objectives of this study aimed to compare antiviral
activities of the monomeric and polymeric units. Overall, the polymeric PAC’s showed a higher
antiviral effect as compered to monomeric catechins. PAC’s isolated from both blueberries and
cranberries were observed to have higher effect than commercial procyanidin B2. HAV was
found to be the most resistant to monomeric treatments amongst the four tested viruses, followed
by AiV and MNV-1. This provides insights about the structural bioactive units that can be
beneficial in the design of appropriate preventive anti-viral therapies from natural sources.
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Extensive research is being carried out to understand the interaction of natural
polyphenols with the viruses and their host cells. Researchers have proposed several theories as
to the effects of plant polyphenols in vitro. Berry PACs were reported to have an effect on
penetration of herpes simplex virus-2 (HSV-2) to the host cells, without much effect on viral
attachment (23). In another study with HSV-2, PAC from an African resurrection plant was
found to inhibit both virus attachment and penetration (24). Black raspberry juice was shown to
be effective in reducing plaque formation of MNV-1 with pre-treatment of host cells that
prevented binding of the viruses and thus subsequent infection of host cells by treated viruses,
however post treatment of cells after infection was not shown to have any significant effect
suggesting that antiviral activity occurred at the point of attachment or entry and not after
infection or on replication (15).
In this study, B-PAC was found to prevent viral adsorption to the host cells to a certain
extent, with lesser effects on viral replication, similar to the results reported by Oh et al., 2012
with black raspberry juice. These findings are also in agreement with the study conducted with
permisson extract where no significant effect pre or post infection was reported and that the
maximal antiviral activity was obtained by direct treatment of the virus particles (25). Similar
findings were reported for ginsenoside extract (5 μg/mL) treatment against HAV, where a very
low reduction in titers was reported when the host cells were pre treated with the extract (26).
In previous studies, similar results with GSE on viral adsorption of FCV-F9, MNV-1, and
HAV was reported, with less effect on replication (14). However, PAC from blueberry leaves
was shown to have a pronounced effect on replication of hepatitis C (HCV) (which is an
enveloped virus) virus by inhibiting expression of NS-3 gene (non-structural gene-3), along with
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blocking of nuclear ribonucleoprotein essential for subgenomic replication (27). Thus, the
mechanism of action seems to differ depending on the virus (enveloped versus non-enveloped)
and the source of PAC.
Antiviral activity of monomeric and polymeric units for PAC was compared in this study
in order to understand if a particular subunit had a higher antiviral activity and that which
component contributes more towards the antiviral effect of B-PAC. FCV-F9 titers were reduced
to undetectable levels with 1 mg/ml B-PAC after 5 min, whereas with catechin hydrate and
procyanidin B2, a treatment time of 3 h was needed to exert the same effect. In case of MNV-1,
1 mg/ml B-PAC reduced titers to undetectable levels within 3 h, however procyanidin B2 at 1
mg/ml reduced MNV-1 titers by 1.23 log PFU/ml and catechin hydrate to undetectable levels
only after 24h. Similar observations were reported for HAV with reduction to undetectable levels
within 3h with 1 mg/ml B-PAC, however no significant change in titers was observed with either
catechin or procyanidin B2 after 24h. B-PAC at 1 mg/ml reduced AiV titers by 2.45 log PFU/ml
after 24h, however catechin and procyanidin B2 at 1mg/ml led to a reduction of 0.66 and 0.67
log PFU/ml after 24h. These comparisons indicate that the individual subunits alone do not
contribute to the antiviral activity but the PAC in its entirety with its polymeric structure is
necessary to cause viral reduction.
With regards to effects on viral structure, in the current study, TEM observations showed
that the B-PAC treatment had a pronounced effect on the structure of the viral particles where
visible damage to the outer capsid was seen with disruption of the capsid and release of internal
contents for FCV-F9, MNV-1 and HAV. The treatment material was also seen to bind to viral
particles in some fields of observations. Binding of the treatment material to viral particle could
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block the binding of the virus capsid to the host cell receptors, and prevent host attachment. This
finding is also consistent with the reduction in the titers observed in the host binding/attachment
assays. Thus, the B-PAC treatment seems to exert its antiviral activity by destroying the viral
capsid and blocking the binding receptors, both leading to prevention of host attachment.
However, no significant damage to the viral capsid by the treatment was observed for Aichi
virus.
With regards to understanding the effect of treatments on viral capsid through ELISA, no
clear mechanism could be established given the high background, and the non-specific binding
of the primary antibody to PGM. Thus, further research to screen for specific primary antibodies
for use and optimization of the ELISA-PGM binding assay is on-going. There are several other
methods proposed in the literature that can be carried out to distinguish between intact or
damaged capsid. Intercalating dyes such as propidiummonoazide along with RT-PCRhave been
used to distinguish between infectious and non-infectious enteric virus (Coxsackievirus,
poliovirus, echovirus, and Norwalk virus) particles and could distinguish noninfectious or
inactivated viruses treated at 72°C and 37°C, however, the method could not detect enteroviruses
that were rendered noninfectious by treatment at 19°C (28). The principle of PGM binding to
distinguish intact and non-intact capsid could also be tested using a different method of detection
such as RT-PCR, which could overcome the problem of high background in the control (29).
Nonetheless, this data presented in this research provided insights on the
structural units of polyphenols that have higher antiviral activity, their effects on viral attachment
to host and replication, and on viral structure by TEM. Overall, gaining insights on the effect of
individual subunits of the tested polyphenols and their mode of action on the target viruses is
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essential towards designing future animal feeding studies, clinical trials and potential antiviral
therapies.
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Appendix D
Table 4.1 Effect of monomeric catechins and procyanidin B2 on FCV-F9 titers at 37oC over 24h
Recovered titer (Log PFU/ml)
Time

(hour)
1
3
6
24

Catechin
hydrate
(5 mg/ml)

PBS
(pH 7.2)

4.71 ± 0.18A
4.71 ± 0.15A
4.77 ± 0.01A
4.73 ± 0.04A

0C
0C
0C
0C

Catechin
hydrate
(1 mg/ml)

4.73±0.37A
3.97±0.16B
0C
0C

Procyanidin
B2
(1 mg/ml)

Procyanidin
B2
(0.5 mg/ml)

4.04±0.24 AB
0C
0C
0C

4.45±0.05A
0C
0C
0C

Different letters denote significant differences when compared between each column (p<0.05). Detection limit for the assay is 2 log PFU/ml.

Table 4.2 Effect of monomeric catechins and procyanidin B2 on MNV-1 titers at 37oC over 24h
Recovered titer (Log PFU/ml)

(hour)

PBS
(pH 7.2)

Catechin
hydrate
(5 mg/ml)

3
6
24

4.80 ± 0.07 A
4.41 ± 0.04 A
4.64 ± 0.04 A

3.04 ± 0.20 B
0C
0C

Time

Catechin
hydrate
(1 mg/ml)

Procyanidin
B2
(1 mg/ml)

Procyanidin
B2
(0.5 mg/ml)

4.38±0.09 A
4.63±0.03 A
0C

4.55±0.16 A
4.67±0.08 A
3.41±0.15 B

4.65±0.05 A
4.49±0.08 A
4.43±0.07 A

Different letters denote significant differences when compared between each column (p<0.05). Detection limit for the assay is 2 log PFU/ml.
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Table 4.3 Effect of monomeric catechins and procyanidin B2 on HAV titers at 37oC over 24h
Recovered titer (Log PFU/ml)
Time

(hour)
3
6
24

PBS
(pH 7.2)

Catechin
hydrate
(5 mg/ml)

Catechin
hydrate
(1 mg/ml)

Procyanidin B2
(1 mg/ml)

Procyanidin B2
(0.5 mg/ml)

4.68 ± 0.08 A
4.64 ± 0.10 A
4.40 ± 0.04 A

4.64 ± 0.03 A
4.64 ± 0.05 A
4.64 ± 0.03 A

4.56 ± 0.16 A
4.72 ± 0.05 A
4.74 ± 0.04 A

4.64 ± 0.04 A
4.68 ± 0.04 A
4.44 ± 0.05 A

4.77±0.04 A
4.70±0.03 A
4.30±0.03 A

Different letters denote significant differences when compared between each column (p<0.05). Detection limit for the assay is 2 log PFU/ml.

Table 4.4 Effect of monomeric catechins and procyanidin B2 on AiV titers at 37oC over 24h
Recovered titer (Log PFU/ml)
Time

(hour)
3
6
24

PBS
(pH 7.2)

Catechin
hydrate
(5 mg/ml)

Catechin
hydrate
(1 mg/ml)

Procyanidin B2
(1 mg/ml)

Procyanidin B2
(0.5 mg/ml)

4.40 ± 0.06 A
4.46 ± 0.03 A
4.30 ± 0.22 A

4.04 ± 0.26 A
3.58 ± 0.03 B
3.35 ± 0.18 B

3.63 ± 0.04 B
3.64 ± 0.02 B
3.64 ± 0.03 B

3.99±0.27 A
3.97±0.16 A
3.63±0.03 B

4.17±0.02 A
4.34±0.06 A
4.33±0.05 A

Different letters denote significant differences when compared between each column (p<0.05). Detection limit for the assay is 2 log PFU/ml.
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Table 4.5 Effect of blueberry proanthocyanidins (B-PAC at 0.5mg/ml) on binding of FCV-F9, MNV-1, HAV and AiV at 37oC
Recovered titer/ Reduction (Log PFU/ml)
Virus

Control

Blueberry PAC

(DMEM)

(0.5 mg/ml)

FCV-F9

6.17 ±0.02A

0

5.54±0.10A

0.63

MNV-1

5.76±0.07A

0

5.22±0.10A

0.54

HAV

5.83±0.02

A

0

5.49±0.09

A

0.34

AiV

4.71±0.04A

0

4.09±0.38A

0.62

Table 4.6 Effect of blueberry proanthocyanidins (B-PAC at 0.5mg/ml) on replication of FCV-F9, MNV-1, HAV and AiV at
37oC
Recovered titer/Reduction (Log PFU/ml)
Virus

Control

Blueberry PAC

(DMEM)

(0.5 mg/ml)

FCV-F9 6.33±0.02A

0

5.95±0.03A

0.38

MNV-1

5.72±0.03A

0

5.49±0.09A

0.23

HAV

5.73±0.03A

0

5.7±0.04A

0.03

AiV

4.73±0.03A

0

4.43±0.10A

0.30
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Figure 4.1 TEM images of FCV-F9 (1a), MNV-1 (2a), HAV (3a) and AiV (4a) controls in sterile
distilled deionized water and FCV-F9 (1b), MNV-1 (2b), HAV (3b) and AiV (4b) treated with
B-PAC at 0.5 mg/ml for 15min, 1 h, 30 min and 1 h respectively; controls in sterile distilled
deionized water; and B-PAC background control (5).
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1a

1b

2a

2b

3a

3b

Figure 4.1 Continued
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4a

4b

5

Figure 4.1 Continued
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Chapter 5 Conclusion
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With the rise in the number of foodborne diseases caused by enteric viruses, there is a
need to develop effective mitigation strategies to control their spread. In the current absence of
vaccination or effective treatment options for human norovirus infections, natural alternatives are
being evaluated (141). Plant derived polyphenols and their associated health benefits as
antimicrobials against bacteria are well established (142-145). Blueberries are known to have a
broad spectrum of health benefits such as prevention of cardiovascular disorders, age-induced
oxidative stress, inflammatory responses, and diverse degenerative diseases along with anticarcinogenic, neuro-protective, cardio-protective, antibacterial, and antiviral properties (148).
This study determined that blueberry proanthocyanidins (B-PAC) and commercial
blueberry juice (BJ) have a significant effect in reducing the titers of human norovirus surrogates
(FCV-F9 and MNV-1), HAV, and AiV in a dose (for B-PAC) and time-dependent manner. For
B-PAC to be used as a therapeutic antiviral agent, evaluation of its effectiveness in model food
systems is important. B-PAC was examined for it antiviral activity in two model food systems,
namely apple juice and 2% milk. These systems were chosen for their high carbohydrate and
sugar content (apple juice) and for their high protein and lipid content (milk). Antiviral activity
of the treatments was enhanced in the presence of apple juice, whereas the activity though
retained, was at a reduced level in the presence of milk.
The study of the effects of B-PAC as an antiviral also includes the determination of its
potential effects after consumption. Effectiveness of B-PAC in the gastrointestinal environment
when consumed orally as potential treatment options against the above foodborne viruses was
studied using simulated gastrointestinal fluids (in the absence of available animal models). The
results showed that B-PAC had a significant effect on viral titers under simulated intestinal
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conditions. This study also aimed at understanding the possible mode of action of B-PAC and its
effect on the infectivity and integrity of the tested viral particles through time of addition assays
and transmission electron microscopy. Results showed moderate effect on the viral particles with
either damaged viral capsid or binding by PAC, possibly preventing their attachment to host
cells.
The overall results from this study provided an understanding of the effective optimum
concentration levels of B-PAC and time required to reduce the titers of the target viruses, in
model food systems and under simulated gastrointestinal conditions. Additionally, insights on
the mechanism of action were obtained. In future, studies on developing strategies for sustained
release or encapsulation may be needed. Furthermore, feeding studies using animal models
(using surrogate viruses for human noroviruses in the current absence of suitable animal models
or human feeding studies) as well as toxicity studies are necessary. However, recommendations
for consumption as therapeutic options or health claims should not be made without supporting
clinical trial data and appropriate regulatory approvals.
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